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Abstract
Small heat shock protein 27 (Hsp27) is a ubiquitously expressed molecular chaperone with
roles in many physiological processes. As an ATP-independent molecular chaperone, Hsp27
protects substrates from irreversible aggregation and holds them in a folding competent state for
later recycling into the proteome. Hsp27 proteins form dimers that are assembled into large
oligomeric complexes. Phosphorylation of Hsp27 dissembles the oligomers into chaperone active
dimers. Several missense mutations of Hsp27 are causative for the neurodegenerative disorders
Charcot-Marie-Tooth disease 2F and distal Hereditary Motor Neuropathy IIB. Here I show that
the oligomerization and chaperoning ability of Hsp27 are altered by the Hsp27 mutations: R127W,
R136W, and S135F. I found that the mutations R127W, R136W, and S135F at the dimer interface
of Hsp27 cause a gain of function along with increased oligomerization. Additionally, I found that
increased monomerization of mutants R136W and R127W correlates with instability and reduced
chaperoning activity. The missense mutation T151I, located outside of the dimer interface, had no
effect on chaperone activity nor oligomerization patterns. These results highlight the notion that
oligomerization and efficient chaperoning activity are highly interconnected processes.
Furthermore, I demonstrate that Hsp27 may regulate the release of its substrates through homooligomer interactions that occur between adjacent dimers of Hsp27. I found that stronger homooligomer interactions correlate with decreased chaperone activity and weaker homo-oligomer
interactions correlate with increased chaperoning activity. In addition, I reveal that the mutant
S135F has both increased homo-oligomer interactions and increased binding to substrates
compared to the wild type Hsp27. My data suggest that the mutant S135F may not efficiently
regulate its homo-oligomer interactions. Altered chaperone activity could lead to aberrant binding
of client proteins, removing them from important neuronal processes. This ill-timed chaperoning
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of substrates may be one potential mechanistic mode of disease progression. Together my
dissertation work not only advances the knowledge of how Hsp27 may release its substrate but
also provides insight into how the missense mutations of Hsp27 associated with Charcot-MarieTooth 2F and distal Hereditary Motor Neuropathy IIB affect chaperone activity and substrate
release. These are important contributions to our understanding of how Hsp27 functions as a
chaperone and its role in human diseases.
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Chapter 1: Introduction
1.1 MOLECULAR CHAPERONES
The proteome is a vast collection of proteins each of which contribute to the maintenance of
cellular homeostasis [1-3]. Diverse environmental and physiological stressors can lead to various
deleterious effects including structural damage of proteins [1, 3, 4]. With so many threats
overwhelming the integrity of the proteome it is imperative that the cell ensures a robust defense
mechanism to keep its proteins structurally viable and functional [1, 5]. Cellular stressors such as
heat shock can often result in partial protein misfolding that can then lead to various disorders
including neurodegeneration [3, 5]. The integrity of protein structure and function is maintained
by a class of proteins known as molecular chaperones [4, 6, 7]. These molecular chaperones
sustain protein homeostasis through assistance with protein folding or the stabilization of
partially misfolded proteins [1, 4]. A subclass of molecular chaperones, known as heat shock
proteins, can assist in the folding of nascent polypeptides or aid in the stabilization and the
refolding of non-native proteins [7-10]. They are also involved in other pathways such as
degradation of irreversibly damaged proteins and unfolding of other proteins for translocation
across a membrane [11-13].
1.2 HEAT SHOCK PROTEINS
Heat shock proteins are broadly conserved amongst six major classes. These include
Hsp100, Hsp90, Hsp70, Hsp60, Hsp40 and the small heat shock proteins [2, 4, 6, 8, 10, 11]. The
larger heat shock proteins, such as Hsp60, are classified as chaperonins and require the
hydrolysis of ATP to actively refold denatured client proteins [6]. Small heat shock proteins
(sHsp) are molecular chaperones that do not require the hydrolysis of ATP [14, 15]. Their
primary role is to maintain a partially denatured protein in a folding-competent state to protect it
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from irreversible and detrimental aggregation [2, 16]. This dissertation will focus on the small
heat shock protein 27 (Hsp27), a ubiquitously expressed chaperone involved in many
physiological and metabolic pathways [17]. In addition to protein folding, it has been implicated
in the regulation of redox states, stabilization of the cytoskeleton, anti-apoptotic activity, and in
important interactions with transcription factors and mRNA processing proteins [8, 18, 19].
Hsp27 (HspB1) belongs to the subgroup of small heat shock proteins that encompass ten human
sHsp. These small heat shock proteins are encoded by the genes HspB1-10 and have been
categorized into two main classes [2, 3, 20]. Class I sHsp include HspB1 (Hsp27), HspB5 (α-Bcrystallin), HspB6 (Hsp20), and HspB8 (Hsp22) [2, 21]. These sHsp are widely distributed with
expression in nearly all cells and tissues where they perform various roles [21-23]. The second
class of small heat shock proteins include HspB2, HspB3, HspB4 (αA-crystallin), HspB7
(cvHsp), HspB9 and HspB10 (ODF1) and are restricted to certain types of tissues such as the
eyes, heart, and testes [2, 21].
1.2.1 Small Heat Shock Protein 27 (Hsp27)
Small heat shock proteins are characterized by a conserved sequence of approximately 80
to 100 residues known as the α-crystallin domain (ACD) [2, 8, 20, 24]. The ACD is flanked by a
variable hydrophobic amino terminal region (NTR) and a short flexible c-terminal region (CTR)
[25-27] (Figure 1). Small heat shock proteins form dimers via β-sheets formed by the ACD.
These dimers serve as building blocks of class 1 sHsp that organize into large oligomeric
complexes that are stabilized by their N-terminal and C-terminal regions [25, 28-30]. The dimers
are thought to be the smallest functional form of small heat shock proteins [31, 32]. These
complexes engage in rapid dimer exchange creating a dynamic equilibrium between large
multimers of various sizes and dimers [14, 15, 25, 33] (Figure 2). The stress pathway activates

2

p38 mitogen activated protein kinase, which in turn phosphorylates mitogen activated protein
kinase activated protein kinase (MAPKAPK2) [2, 34, 35]. Phosphorylation by MAPKAPK2
shifts the equilibrium to small oligomers and dimers whereas protein phosphatase 2A activity
reverses this process and favors the formation of large multimers [2, 34, 36, 37] (Figure2). This
system might be a way to store large amounts of Hsp27 to quickly react to stress without the
need for de novo protein synthesis [38].
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Figure 1. Hsp27 Structural organization. (A) Hsp27 is made up of three regions where each
region is identified as NTR, ACD, and CTR. The residue numbers that make up each region are
also denoted. (B) The amino acid sequence of the disordered NTR is listed and the two motifs
WD/EPF and SRLFDQxFG are highlighted with red and green, respectively. β-strand β-2 is
highlighted in cyan. (C) The ACD amino acid sequence is listed as well as the location of βstrands and their connecting loops. The ACD is the only part of Hsp27 that is ordered (PDB
2N3J). (D) Hsp27 disordered CTR highlighting the IXI/V motif in red.
1.2.1.1 Features of the Hsp27 Regions
Three major structural regions of Hsp27 can be defined by the structural and functional
distinctions between them. The N-terminal region (NTR) of Hsp27 is composed of the first 93
residues and nearly 50% of the Hsp27 primary sequence [24] (Figures 1 A,B). The NTR is
inherently disordered and composed of predominantly hydrophobic and aromatic residues. It is
thought to be primarily responsible for driving/stabilizing higher order multimers of Hsp27 [2].
Hsp27 is phosphorylated via the p38 MAPK pathway by MAPKAPK2, which occurs at serine
residues 15, 78, 82 of the NTR [13, 32] (Figure 1B). In its unphosphorylated state Hsp27 exists
as large polydisperse oligomeric species with a molecular weight of up to ~650kDa [39].
Experimental evidence has demonstrated that tunability of Hsp27 oligomeric size can be
achieved through stepwise phosphorylation of the three phosphorylation sites [31, 40].
Phosphorylation of all three sites yields smaller oligomers and dimers whereas phosphorylation
of one or two sites results in intermediately sized oligomers [31, 40]. Evidence suggests that the
regulation of multimers influences the function of Hsp27 [31, 40]. Larger multimers are thought
to act as a storage state for chaperone active dimers where regulation by phosphorylation acts as
a switch that activates chaperone activity when needed [31, 40, 41]. Truncation studies have
confirmed that regions within the NTR play a large part in production and stability of higher
order multimers [42]. The NTR is a highly flexible region that can adopt several conformations
to facilitate oligomerization.
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The Hsp27 α crystalline domain (ACD) is comprised of residues 94-168 that are arranged
into six β-strands that form two β-sheets [43-45] (Figure 1C). This immunoglobulin-like fold of
the ACD is conserved amongst various organisms in both sequence and structure [24, 46]. The βstrands denoted as 4, 5, and extended strands 6+7 make up one β-sheet, whereas β-strands 3, 8,
and 9 form another β-sheet [26, 47]. Residues on the carboxy-terminal side of the NTR (84-91)
periodically form a seventh β-strand (denoted β2) that integrates into the β3/β8/β9 β-sheet [47,
48] (Figure 1B). The driving force for Hsp27 dimerization is hydrogen bonding and electrostatic
interactions between ACDs. This occurs by pairwise alignment of the extended β6+7 strands in
an antiparallel 2 register (AP2) creating the dimer interface and an extended β-sheet [24, 25, 30,
49] (Figure 3A). The extended β-sheet is the sum of two β6+7 containing β-sheets forming one
longer extended symmetry related β-sheet. The extended β-sheet and two β3/β8/β9 β-sheets from
each monomer create a groove that is located right above the dimer interface and between the
two β3/β8/β9 β-sheets, therein described as the dimer interface groove [47] (Figure 3B).
Another structurally notable feature of the ACD is the β4/β8 groove which includes a
hydrophobic pocket centered between β-strands 4 and 8 and is located on the outer edge of the
ACD β-sandwich [47, 50, 51] (Figure 3C). Therefore, within a dimer of Hsp27 there are two
hydrophobic grooves located at the edges of each monomer and one shared dimer interface
groove created by the linkage of two monomers [24, 49] (Figure 3D). These grooves provide
regions for several client protein and oligomer binding opportunities.
The C-terminal region (CTR) and extension make up the remaining thirty-seven residues
of the Hsp27 primary sequence (Figure 1A). The CTR has an abundance of polar and charged
residues and is partly responsible for oligomer formation and is thought to aid in solubility of
Hsp27 oligomers and or oligomer/substrate complexes. [18, 49, 52, 53]. The CTR contains a
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well conserved region known as the IXI/V motif at residue positions 179-183 characterized by
alternating isoleucine and valine residues with the central residue being a canonical proline [28,
52] (Figure 1D). This motif contributes to the stabilization of oligomers by interlinking adjacent
dimers. The C-terminal extension consists of the last twenty-two residues and does not contain
any secondary structure [52, 54]. The extension including the IXI/V motif is inherently
disordered and highly mobile [54]. This is partly due to cis-trans isomerization about the 182 and
194 proline residues which causes changes in the adopted disordered states [54].

Figure 2. Hsp27 is organized into higher order structures (PDB 6DV5 and 2N3J). The monomer
of Hsp27 assembles into dimers via the ACD. Dimers in turn interact with each other to form
large highly dynamic multimers. Phosphorylation by MAPKAPK2 dissociates oligomers of
Hsp27 and favors dimer formation while Protein Phosphatase 2A shifts the equilibrium towards
multimer formation.
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1.2.1.2 Hsp27 NTR ACD and CTR Interact to Form Higher Order Complexes
Various hydrophobic peptide regions of the NTR make multiple contacts with two
grooves of the ACD [24]. The distal region of the NTR that encompasses the first thirteen
residues interact with the β4/β8 groove of the ACD (Figure 4). This interaction is thought to be
the result of alternating hydrophobic residues on the distal region of the NTR (6-VPFSLL-11)
considered to be a motif that can bind the β4/β8 groove [24]. The next set of residues of the
NTR, that contain serine-15 and the WD/EPF motif (12-27) bind a negatively charged area made
of loops L3/4 and L5/6 [24] (Figure 4). Interestingly, serine residues 78 and 82, that are distant in
sequence, bind near this NTR binding region [24]. It is suggested that this phosphorylated serine
congregation facilitates regulation of phosphorylation [24]. Additional negative charges,
introduced by phosphorylation, disturb the region, and promote dissociation of the NTR (12-27)
from the negatively charged loops [24, 31].
The remaining segments of the NTR (residues 25-37 and 74-91) bind the groove created
by the dimer interface (Figure 4). For example, the NTR (25-37) contains the conserved
SRLFDQxFG motif [24, 42]. This motif binds at the dimer interface groove much like the NTR
(74-91) that contains the phosphorylation site serine residues [47]. This means that at any given
time, several regions of the NTR are bound to different grooves within the ACD. The β2 strand
of Hsp27 (residues 84-93) also transiently binds the adjacent β3 strand in an antiparallel
orientation [24, 47, 48]. The β2 strand can also become extended and transiently bind the β4/β8
groove of an adjacent dimer [48] (Figure 4).
The CTR of the small heat shock proteins forms transient interactions with regions on the
ACD [53]. As seen with many sHsp the IXI/V motif within the CTR fits into the hydrophobic
β4/β8 groove in an antiparallel orientation [24, 55] (Figure 5). This interaction is like the NTR
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distal motif and the NTR β2 strand binding within the groove (Figure 4). The outer residues of
the IXI/V motif fit into the holes of the hydrophobic groove due to the kink created by the center
proline-182 residue [47, 56]. This is described as an extended formation of the CTR in the transconformation as the canonical proline can undergo cis-trans isomerization about the I-P peptide
bond. [54]. The interaction is found to occur within the same dimeric subunit and between
adjacent dimers as well [51]. The IXI/V motif is considered a short linear motif (SLiM) that
modulates interactions between proteins [51]. In the case of Hsp27, those interactions are
between the CTR, the ACD, and possibly client proteins [51]. A crystal structure of the truncated
Hsp27 ACD co-crystallized with a peptide mimicking the C-terminal IXI/V motif has been
solved (Figure 5). The binding of the CTR IXI/V motif within the hydrophobic groove of the
ACD acts to further stabilize high molecular weight homo-oligomers of Hsp27. It accomplishes
this by transiently linking neighboring dimers indicating that the population of bound and
unbound IXI/V motifs is mixed [49]. The binding combinations for these regions occur within a
dimer and between adjacent dimers. The transient nature of these interacting regions creates a
flexible protein that is unexpectedly stabilized. Hsp27 is a dynamic protein that is continuously
exchanging its binding regions allowing for substrate capture.
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Figure 3. Groove locations in the crystal structure of Hsp27. (A) A ribbon diagram of the Hsp27
dimer (PDB 4MJH). (B) Hsp27 structure seen in panel (A) but in surface representation where
the dimer interface groove is shaded yellow. (C) Hsp27 β4/β8 groove (colored in orange). (D)
Representation of the three grooves on a dimeric unit colored the same as in panels (B, C).
1.2.1.3 Hsp27 Regions Involved in Substrate Capture
The three regions of Hsp27 have distinct roles in substrate capture [23, 26, 57]. The ACD
is thought to bind proteins that aggregate via the amyloid fibril aggregation pathway [2, 3, 23,
56, 58]. Client proteins that aggregate via this mechanism tend to form β-sheet conformations
that resemble β-amyloid fibrils so the attraction between the ACD and the amyloid fibril-like
substrate is robust [23, 59]. The neuronal protein α-synuclein is an established substrate of
Hsp27 that aggregates via the amyloid fibrillar pathway. It was found that full-length Hsp27 and
truncated ACD transiently bind monomers of α-synuclein preventing their formation into fibrils
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[60-62]. The truncated ACD displayed a lower binding affinity for α-synuclein monomers than
the WT indicating that the α-synuclein monomer binding is in large part through the NTR [62].
Additionally, the isolated ACD of Hsp27 cannot bind to α-synuclein fibrils that are already
aggregated [61, 63]. Co-sedimentation experiments of Hsp27 lacking the CTR and in the
presence of α-synuclein fibrils confirmed that the CTR is required to bind the fibrils [63].
Therefore, involvement of the NTR and CTR is required when binding fibrillar aggregates of αsynuclein to prevent their elongation [61, 63]. These experiments suggest that the ACD alone is
not sufficient to protect against amyloidogenic aggregation and that the involvement of all three
regions is required.
Further evidence suggests that there is a strict interplay between the three Hsp27 regions
to regulate chaperone activity [55, 56, 64]. It has been observed that Hsp27 binds Tau, another
protein that aggregates via the amyloidogenic pathway [55, 56, 64, 65]. This is mediated by an
interaction between an IXI/V motif of Tau and the ACD hydrophobic groove suggesting that the
groove provides protective benefits against fibril formation [56]. However, this study also
revealed that using truncated forms of Hsp27 lacking the NTR completely abolished this
protective activity, further complicating the mechanism by which Hsp27 binds Tau [56]. One
study suggested that the chaperone activity of Hsp27 extends beyond the ACD hydrophobic
groove and is actually dependent on interactions of NTR to client protein [55].
It was subsequently determined that a terminal peptide representing the first 13 residues
of the Hsp27 NTR binds the ACD hydrophobic groove that binds Tau fifty residues downstream
of the highly disordered NTR region [24]. These experiments demonstrate a possibility that a
binding competition for the ACD groove exists beyond IXI/V-containing proteins such as Hsp27
CTR, Tau, PCBP1 and others. Mutation of the B4/B8 hydrophobic groove to discourage binding
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between the groove and any IXI/V motif showed an unexpected increase in chaperone activity
towards Tau [56]. This suggests that the ACD region is not the actual site for chaperoning
activity [55]. Instead, there may be a competition between the NTR, CTD, and other IXI/V
containing entities for the hydrophobic groove of Hsp27. Therefore, the role of the ACD
hydrophobic pocket may be to act as a regulatory limiting factor that controls the extent to which
Hsp27 binds and chaperones proteins [18, 56, 58]. Hsp27 can protect a large array of structurally
diverse client proteins by utilizing its dynamic conformational variability. Mutations of Hsp27
can easily disturb this tightly regulated balance and lead to neurodegenerative disorders.
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Figure 4. Map of Hsp27 interacting regions. (A) Each of the monomers is depicted as either blue
or cyan with the dimer interface groove in yellow and the β4/β8 groove for each monomer in
orange. Disordered regions are drawn as either green or magenta lines with the binding motifs as
labeled. Important interaction loops are indicated by arrows. (B) The table at the bottom lists
each of the disordered binding regions and the groove/pocket that bind as described by peptide
mapping.

Figure 5. Hsp27 crystal structure (PDB 4MJH) co-crystallized with peptide mimic of the IXI/V
motif. The peptide (colored in orange) was found bound to the β4/β8 groove as indicated. (A)
Ribbon representation of the dimer illustrating the location of the two bound peptides. (B)
Surface representation of the dimer that better illustrates the β4/β8 groove with the bound
peptide.
1.3 HSP27 AND ITS ROLE IN NEURODEGENERATION
Hsp27 has been implicated in being causative for human neurodegenerative disease. The
main diseases having a direct link to genetic mutations of Hsp27 include Charcot Marie Tooth
disease Type 2F and distal Hereditary Motor Neuropathy IIB. Hsp27 is a ubiquitously expressed
protein with expression patterns in nerve and muscle cells, consequently, missense mutations
naturally cause disruptions in a large area of the body. The molecular mechanism by which these
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single point mutations lead to disease is still not understood however it is thought that these
mutations have an interplay in the premature degeneration of axonal cytoskeleton filaments.
1.3.1 Charcot-Marie-Tooth Disease
Small heat shock proteins can be perturbed by a myriad of inherited and sporadic
mutations that result in the formation of neurological disorders. For example, various missense
mutations in the small heat shock protein 27 (Hsp27) cause the neuropathies Charcot-MarieTooth Disease Axonal Type 2F (CMT2F) and Distal Hereditary Motor Neuropathy 2B
(dHMN2B) [66, 67]. These neuropathies are commonly inherited disorders that exclusively
affect the peripheral nervous system [68]. They are closely related in their key features of disease
progression and only differ by the point mutation that leads to the respective disease. CMT2F is
a subset of the more broadly categorized forms of CMT, specifically characterized by axonal
degeneration of the peripheral nerves [69, 70].
The characteristic symptom of CMT2F includes the slow progressive loss of motor
function manifested as weakness and muscle atrophy of the distal limbs [71, 72]. Additionally,
there can be decreased tendon reflexes of the ankle and legs, as well as physical deformities of
the feet [3, 72]. In cases of sensory neuron involvement, afflicted individuals lose pain and
temperature sensation [73]. The disease, although progressive over many years, does not affect
life span [69]. Individuals with CMT2F typically experience the onset of symptoms during
adulthood and may require treatment through physical therapy, mobility aids, orthopedic shoes,
and/or surgery [71]. More severe forms of CMT2F can result in hearing loss and vocal cord
impairment, in addition to acute distal limb pain [2].
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1.3.2 Distal Hereditary Motor Neuropathy
While CMT2F manifests as a motor and sensory neuropathy, Distal Hereditary Motor
Neuropathy Type II (dHMNIIB) exclusively affects motor neurons [69, 74]. dHMNIIB clinically
presents similarly to CMT2F as they are related diseases caused by some of the same mutations
[67]. Individuals experience lower limb weakness due to muscle loss and deteriorating leg
mobility [67, 75, 76]. The typical onset of disease occurs in individuals between the ages of 15 to
45 and is a progressive disease that severely compromises quality of life [69, 75, 76]. Both
CMT2F and dHMNIIB have autosomal dominant patterns of inheritance indicating that only one
copy of a mutated gene is sufficient to cause disease [69, 71]. These neuropathies are described
as being clinically and genetically heterogenous [67, 75, 77, 78]. This means that the same
mutation can result in different clinical presentations and different mutations can manifest as the
same disease, further complicating the understanding of the patho-mechanisms.
1.4 RATIONALE/GOALS
1.4.1 Characterize the Role of Hsp27 in Neurodegeneration
The key role of Hsp27 is protection of the proteome through its chaperoning activity.
Mutations of Hsp27 may disrupt this critical task by destabilizing the interactions between
chaperone and substrate. The goal of this project was to characterize the Hsp27 disease-causing
mutations in terms of their chaperoning activity and to understand how the point mutations may
affect the oligomerization patterns and secondary structures of Hsp27. To further understand the
role of Hsp27 mutants in the process of disease progression we collaborated with Dr. Han in
generating a Drosophila Melanogaster Model for CMT2F.
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1.4.2 Manipulation of NTR and CTR to stop dimer formation and autoproteolysis
In addition, we probed other areas of the Hsp27 protein to further understand its
mechanisms. We generated NTR and CTR mutants to explore a possible auto-proteolysis
mechanism that could be responsible for Hsp27 activity. Phosphorylation of Hsp27 at three key
serine residues shifts the equilibrium of heterogenous oligomers to a population of smaller
tetramers and dimers. We sought to inhibit this distribution of oligomers by introducing point
mutations at the three serine residues to alanine residues to halt the formation of residual dimers
within the population of dynamic oligomers. In addition, we isolated the region where
degradation of Hsp27 occurs and created point mutations to further understand the chaperone
mechanisms of Hsp27.
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Chapter 2: Methodologies of Molecular Cloning
2.1 BACKGROUND
Molecular cloning is a term used to collectively describe the process of creating many
copies of genetic information encoding for a specific protein of interest to insert into a vector of
choice for production purposes [79]. There are many variable routes among cloning procedures,
the following will be explained in detail; PCR site-directed mutagenesis, restriction enzyme
digest, ligation, transformation, and plate selection.
PCR site-directed mutagenesis (SDM) is a method used to make specific alterations at the
level of double stranded DNA such as insertions, deletions, and substitutions to study the effects
these manipulations have on protein structure and activity. This technique is popularly used
within the scope of studying disease as a considerable number of diseases arise from genetic
mutations. To perform PCR site-directed mutagenesis short oligonucleotides are designed prior
to the reaction. Four primers are designed: the forward and reverse primers and the forward and
reverse mutant primers also known as internal primers [80, 81]. The forward and reverse primers
are short sequences of nucleotides complementary to the 3 prime ends of the target gene. These
are required in ensuring the synthesis of the entire gene product is amplified. The forward and
reverse mutant primers alter the nucleotide sequence, in this context a base substitution [82].
Usually, the center of the mutant primers contains the codon to insert the altered base pair and
flanking this codon the sequences are complementary to the template strand. This ensures
annealing of the mutant primers to the template and incorporation of the desired mutation.
PCR site-directed mutagenesis entails three PCR reactions; the first two creating the two
halves of the gene with the incorporated mutation and the third combining the halves to amplify
the entire gene with the corresponding mutation [81, 83]. In its simplest form a PCR reaction
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requires a DNA polymerase, free nucleotides, the template cDNA of the desired gene, and the
appropriate primers. These contents are subjected to several cycles of denaturation, annealing,
and extension to produce the final product of the amplified gene. Separation of double stranded
DNA occurs at elevated temperatures close to 98°C, after denaturation the reaction temperature
is quickly decreased to a temperature corresponding to the melting temperature of the primers to
allow the binding of the primers to their complementary sequences on the DNA strands, this is
referred to as the annealing phase [83]. Once the primers have annealed the last phase, extension,
proceeds as the DNA polymerase is now able to bind to the double stranded DNA at the site of
the bound primers and extend the sequence by incorporating the free nucleotides according to the
complementary sequence. These steps are repeated a total of twenty-five to thirty-five times,
each time exponentially amplifying the gene product resulting in millions of copies of the desired
sequence.
To perform site-directed mutagenesis two reactions are set up, each containing the basic
elements required for a PCR reaction. The forward primer and reverse mutant primer create one
half of the target gene and the reverse primer and forward mutant primer create the other half
[81, 83] (Illustration 1). After several cycles of denaturation, annealing and extension each
reaction contains one side of the gene; more specifically one reaction contains the gene product
to the left of the mutation and the other reaction contains the gene product to the right of the
mutation (Illustration1). In the third reaction the only requirement is to combine the two halves
by adding DNA polymerase and free nucleotides and subjecting the contents to the appropriate
cycles of denaturation, annealing, and extension [83] (Illustration 1). The two sides of the gene
will bind to each other in the annealing phase because they are complementary to each other and
the entire gene product with the anticipated base change will be amplified.

17

Illustration 1. PCR reactions and products to generate site-directed mutagenic genes.
The next procedure to follow in the traditional cloning method is known as restriction
enzyme digest. This is a strategy used to create compatible ends on the gene product to be
unidirectionally inserted into a compatible plasmid. This technique works by utilizing the
activity of restriction enzymes which are proteins that work to defend bacteria from infection by
cutting foreign DNA [84]. By using these enzymes and their DNA recognizing and cutting
activity it is possible to generate compatible ends which are also known as sticky ends that are
complementary to the sticky ends generated on the plasmid of choice [85, 86]. This technique
works because restriction enzymes recognize short consecutive sequences of DNA known as
palindromes (or recognition sequences); wherein the 5’ to 3’ sequence on one strand is the same
as the 5’ to 3’ sequence on the complementary strand [85]. Once the restriction enzyme has
recognized and bound its recognition sequence it cuts the double stranded DNA in such a way
that it leaves an overhang. This overhang or short single stranded sequence of DNA is
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complementary to the overhang sequence on the plasmid also treated with the same restriction
enzyme [85].
By choosing the appropriate restriction enzymes based on the order of the restriction
enzyme sequences on a certain plasmid it is possible to control the orientation of the insertion of
the gene product into the vector. This is assured by first picking two restriction enzymes based
on the proximity of their restriction enzyme sequences to the open reading frame on the plasmid;
whichever is closer will dictate its placement on the 5’ end of the forward primer [86]. The
restriction enzyme sequence farther from the start of transcription on the plasmid will thus be
placed on the 5’ end of the reverse primer. Therefore, the forward and reverse primers must
contain the appropriate restriction enzyme sequences to incorporate those sequences at the ends
of the gene for compatible ends generation.
The amplified gene containing the restriction enzyme sequences at both its ends is then
incubated with the respective restriction enzymes to generate those sticky ends. The plasmid of
choice is also incubated with the same restriction enzymes to ensure compatibility between the
vector and gene and unidirectional insertion of the gene [85, 86]. After the digestion reaction has
completed it is necessary to isolate the digested products from any uncut product and other
undesirable products. This is done through electrophoresis followed by gel extraction; the
digested reaction is loaded onto an agarose gel where the digested product can be targeted based
on a molecular standard and excised from the gel. DNA purification ensues, and the final product
is ready for the next phase of molecular cloning.
The next step is ligation; this process involves the sealing of the sugar phosphate
backbone. After gene and plasmid have been digested and purified they are joined and incubated
with the enzyme T4 DNA ligase [87]. This enzyme is involved in the DNA repair system and
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DNA replication where its function protects the genome from breaks in the DNA. By using the
natural role of DNA ligase, it is possible to create genetically recombinant plasmids. The first
phase of this procedure involves combining the digested gene insert and plasmid in a ratio of 3 to
1. This is done to increase the probability of compatible ends meeting and forming hydrogen
bonds between complementary bases [88]. The temperature for this reaction is kept low to
increase the chances of insert and vector colliding and being held in place by hydrogen bonding
long enough for DNA ligase to recognize and seal the nicks. The ligase then catalyzes the
formation of a phosphodiester bond between the 3’ hydroxyl and 5’ phosphate [86, 87]. The
reaction involves an AMP nucleotide being transferred from the enzyme to the phosphate group
which leaves the phosphorous atom electron depleted. A nucleophilic attack of the 3’ hydroxyl
group to the 5’ phosphate liberates the nucleotide and creates a covalent bond that effectively
seals the sugar phosphate backbone. The resulting product is a recombinant plasmid that is ready
for transformation.
Ligation free cloning also known as restriction enzyme free cloning is an alternative
method to traditional molecular cloning methods. The advantage of this method is that it does not
require the use of restriction digest and ligase enzymes and is therefore cost effective. The
method works by inserting the desired gene product directly into a circular plasmid derived from
PCR techniques [89]. A desired gene product is synthesized with primers that contain sequence
extensions complementary to the target plasmid. The gene with the overlap extensions is
amplified and work as “megaprimers” that can now be used in a secondary PCR reaction where
the DNA product is double stranded plasmid, with double nicks, and the desired gene inserted
into the plasmid. You can introduce mutations or alterations with this method by using parental
plasmid that already contains the desired gene template. Primers are complementary to the insert
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except at the region where the base substitution or alteration is required. In the secondary PCR
reaction, the megaprimers are used to generate plasmid with the gene product and desired
mutations. The reaction is then incubated with Dpn1 enzyme which is a restriction enzyme that
digests at methylated adenosines [89]. The parental plasmid is only methylated and so the
enzyme treatment ensures that only newly synthesized plasmid remains.
Transformation is the process of inserting the recombinant plasmid into expression cells
of choice. These cells are competent cells due to their tendency to readily uptake plasmids [90]
This occurs due the repeated treatment of the cells with various solutions of cations. [91]. The
cations imbed themselves in the membrane of the cell and increase the opportunity for a plasmid
to enter the cell [90]. When competent cells are incubated with plasmid the cations in the
membrane electrostatically attract the negatively charged DNA to the surface of the cell
membrane and effectively hold it in place [90, 92]. When the cell membrane opens during heat
shock the chances of the plasmid entering the cells are increased due to the close proximity of
the plasmid.
The basic protocol for a transformation involves incubating competent cells with plasmid
on ice for about 30 minutes. This allows for diffusion of the plasmid throughout the suspension
of cells and creates opportunities for interaction with the positively charged ions in the
membrane. Pipetting is not recommended as the competent cells are overly sensitive and must be
treated with care therefore, diffusion is the best method of mixing the plasmid. After mixing, the
cells are heat shocked for a few seconds at 42°C, this creates transient breaks in the membrane
and the chance for the plasmid to enter the cell occurs. Only one plasmid uptake is sufficient for
transformation purpose as the next step involves incubation of the cells at 37 degrees with
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agitation to grow the cells. The cells will multiply along with any cells that up took plasmid and
thus produce thousands of plasmid-containing cells [92, 93].
Modern cloning vectors include selectable antibiotic resistance markers that will only
allow cells that contain the plasmid to survive in an environment containing antibiotic. This
entails plating the grown cells onto agarose plates that contain the specific antibiotic the plasmid
has resistance to [91]. This will ensure that colonies grown on the plates contain the plasmid
however this does not mean the plasmid contains the gene of interest. Colony PCR is a method to
ensure the successfully transformed plasmid contains the recombinant gene of interest.
2.2 MATERIALS AND METHODS
The Hsp27 constructs including WT, and the disease-causing mutants R127W, S135F,
R136W, T151I and P182L were prepared by traditional cloning methods. This included PCR,
site-directed mutagenesis, restriction enzyme digestion, and ligation and transformation. The
NTR and CTR mutants were also generated by traditional cloning methods with the inclusion of
ligation free cloning to create the NTR mutants. All constructs were verified by DNA sequencing
analysis performed by Ms. Ana Betancourt at the genomic analysis core facility.
2.2.1 PCR-Site Directed Mutagenesis of Hsp27 WT and Disease-Causing Mutants
Cloning of Hsp27 wildtype (WT) and disease mutants began with primer design for
preparation of inserts. Primers were designed and ordered from Integrated DNA Technologies
(IDT), the following sequences represent the primers used for PCR to generate recombinant gene
sequences of Hsp27 WT and mutants R127W, S135F, R136W, T151I, and P182L (Table 1).
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Table 1. Primers used to generate Hsp27 constructs

Reactions were set up according to the New England Biolabs protocol: PCR Using Q5® HighFidelity DNA Polymerase. A total reaction volume of 50µL contained 0.2 U/µL Q5 HighFidelity DNA polymerase, 200µM dNTPs, 0.5µM forward primer, 0.5µM reverse primer, 1ng/µl
template DNA, and 10µL GC Enhancer in a 1X Q5 reaction buffer. Following set up, the
polymerase chain reaction was initiated by subjecting the samples to 30 cycles of denaturing,
annealing, and extension. Table 2 displays the thermocycling conditions for Hsp27 WT gene
construct.
Table 2. Thermocycling Conditions for Amplification of Hsp27 WT Recombinant Gene

The asterisk denotes where the thermocycling conditions varied for each sample reaction due to
differences in the melting temperatures (Tm) of the primers and variable lengths of gene
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products. All reactions contained the same template DNA therefore additional PCR reactions for
the mutant genes were required to follow the site-directed mutagenesis procedure. Two reactions
were set up to generate the two halves of the gene with the correct substituted base pair.
Following DNA purification by excision from a 0.8% agarose gel the amplified sequences were
combined in the final reaction to amplify the full-length gene sequence (Figure 2A).
Mutant genes were amplified by the three-step PCR reaction procedure with the following
components for each reaction: Reaction 1 contained 0.2 U/µL Q5 High-Fidelity DNA polymerase,
1X Q5 reaction buffer, 200µM dNTPs, 0.5µM WT forward primer, 0.5µM mutant reverse primer,
1ng/µl template DNA, and 10µL GC Enhancer. Reaction 2 contained 0.2 U/µL Q5 High-Fidelity
DNA polymerase, 1X Q5 reaction buffer, 200µM dNTPs, 0.5µM WT reverse primer, 0.5µL
mutant forward primer, 1ng/µl template DNA, and 10µL GC Enhancer. Reaction 3 contained 0.2
U/µL Q5 High-Fidelity DNA polymerase, 1X Q5 reaction buffer, 200µM dNTPs, and the purified
gene segments from the two previous reactions.
Thermocycling conditions for each reaction step can be referenced from Table 2 with the
following changes in annealing temperature and extension time for each reaction step. Following
amplification, products were run on a 0.8% DNA agarose gel to analyze the length of the
sequences synthesized. Reaction 1 theoretically generates an amplicon around 193 base pairs
(bp), reaction 2 should generate a 425 amplicon, and the halves combined in reaction 3 should
produce the full length Hsp27 sequence of 618 bp. Figure 2A shows the gene products of
reactions 1, 2, and 3 for mutant R127W, the other five mutants S135F, R136W, T151I, and
P182L displayed comparable results.
All amplicons displayed comparable results with slight variances in length due to the
specific base substitution needed to generate the mutant genes. Depending on the sight of the
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mutation the reaction 1 and 2 products varied in length relative to each other, but all final
reaction products were exactly 618 bp in length including Hsp27 WT. The six final reaction
products were run on a 0.8% agarose gel in preparation for purification via gel excision using a
QIAquick Gel Extraction Kit. Recovered gene product concentrations were obtained using a
spectrophotometer, 280/260 ratios were within the acceptable ranges.
2.2.1.1 Restriction-Ligation Free Cloning of Hsp27 NTR Mutants
The molecular cloning methods described above were unsuccessful in generating the
NTR mutants. Instead, we used restriction ligation free cloning to generate these gene products.
Only the triple serine mutant S15,78,82A was unsuccessful and was designed and ordered
through Genscript.
Table 3. Primers used to generate the NTR Hsp27 constructs

The forward and reverse primers listed in Table 3 were used to generate the megaprimers in the
primary PCR reaction. The reaction was setup like Table 1 and the thermocycling conditions
were setup similarly to Table2 with variable differences in the annealing temperature and
extension times. The PCR reactions generated megaprimers for each of the three constructs
S15A, S78A, S82A with target lengths of 51, 121, and 133 base pairs, respectively. The
megaprimers were purified by gel extraction purification methods and prepared for the secondary
PCR reaction. The secondary PCR setup varied in that the parental plasmid was fixed at a total
amount of 100ng and the megaprimers were setup at a 2-fold molar excess. The thermocycling
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conditions were setup according to Table 4. The reaction was then treated with 20 units of Dpn1
enzyme for 2 hours at 37°C. Figure 6 shows the plasmid products, linearized for electrophoresis
purposes, that were cloned with the megaprimers for S15A, S78A, and S82A. Once the parental
plasmids were cleaved the plasmid product was directly transformed into BL21(DE3) Competent
E. coli cells purchased from Sigma.
Table 4. Thermocycling Conditions for Amplification of NTR Hsp27 Constructs Recombinant
Gene

Figure 6. Linearized plasmid products of vectors containing the Hsp27 S15A, S78A, and S82A
gene products. The parental plasmid was digested by DpnI.

26

2.2.1.2 Cloning of Hsp27 CTR Mutants
The CTR mutants, F185Y, E186Q, double mutant and the C-terminal deletion were successfully
prepared by traditional cloning methods. Table 5 represents the primers used to generate the gene
products through site-directed mutagenesis. The C-terminal deletion product was generated by
traditional PCR where the reverse primer was complementary to the sequence just before the
desired truncation. The PCR reactions were setup according to Table and the annealing
temperature was optimized by gradient PCR.
Table 5. Primers used to generate the CTR Hsp27 constructs

2.2.2 Restriction Enzyme Digest and Ligation of Hsp27 Genes
Amplified inserts were digested with restriction enzymes to produce compatible ends for
unidirectional insertion into plasmid vector pET-22(b)+ purchased from IDT. A total of ten
digestion reactions were set up to prepare the gene inserts and plasmid for restriction enzyme
digest. Enzymes NdeI and XhoI were used for all inserts and vector. Restriction enzyme double
digestion reactions were set up for inserts and plasmid as follows: 50µL total reaction volume
contained 1µg of DNA, 5µL of 10X CutSmart Buffer, 10 units of restriction enzyme NdeI, and
10 units of restriction enzyme XhoI. The mixtures were incubated overnight at 37°C followed by
heat inactivation at 70°C for ten minutes. Digested products were run on a 0.7% agarose gel for
gel purification using a QIAquick Gel Extraction Kit. The concentration of the purified products
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was taken by a Beckman spectrophotometer. Figure 7B shows DNA products before and after
digestion of plasmid pET-22(b)+ and WT.
Successful digestion of vector pET-22(b)+ can be confirmed from the DNA gel
since digested plasmid in lane 3 runs slightly faster than the undigested plasmid in lane 2. The
double digestion liberated DNA approximately 500 bp in length, this corresponds to the stretch
of DNA exactly in between the two restriction enzyme sequences on the plasmid. Furthermore,
circular DNA does not migrate through a DNA gel with as much ease as linear DNA does, this
can be seen by the slower migration of uncut circular plasmid in lane 2 vs linearized plasmid in
lane 3. Lanes comparing WT gene before and after digestion cannot be confirmed with
qualitative analysis of the gel because the digestion only results in a loss of 6 bases. Digested
products of all mutants showed equivalent results to the WT.
Following gel purification of the digested products ligation reactions were set up to ligate
each insert to the plasmid vector for subsequent transformation into competent cells. The ligation
protocol with T4 DNA Ligase from New England Biolabs was referenced for ligation set up.
Each digested insert product was incubated in a 3 to 1 molar ratio with the digested plasmid
pET-22(b)+. The reactions to generate recombinant plasmids with the corresponding gene of
interest for WT and mutants, were set up in the following way: 2µL 10X T4 DNA ligase buffer,
1 µL T4 DNA ligase 50ng vector DNA, 37.5 ng insert DNA in a total reaction volume of 20µL.
The reactions were homogenized and incubated overnight at 16°C followed by heat inactivation
at 65°C for ten minutes.
2.2.3 Transformation and Colony PCR of Hsp27 and Mutants
Recombinant constructs were transformed into BL21(DE3) Competent E. coli cells
purchased from Sigma. Six tubes of competent cells were thawed in ice for ten minutes, 100ng of
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each recombinant plasmid was added to the cell mixture and carefully mixed. The mixtures were
placed on ice for 30 minutes to allow for further homogenization via diffusion to increase the
chance of uptake by the cells. The suspensions were then heat shocked at exactly 42°C for ten
seconds then placed in ice for another 5 minutes. The transformed cells were recovered in 950µL
of SOC media and rotated at 250 rpm in an incubator set to 37°C for one hour. Selection plates
containing ampicillin at a working concentration of 100µg/mL were warmed to 37°C. Four
dilutions of each transformation were made at 1:20, 1:10, 1:5, and 1:2 from which 100µL of each
dilution were plated onto a selection plate and incubated overnight at 37°C.
To confirm transformation of recombinant plasmid, colony PCR was done to test for the
presence of the target gene. The colony PCR reactions were set up according to CloneTech
protocol: Colony PCR with SapphireAmp Fast PCR Master Mix. Each reaction mixture
contained 25µL of SapphireAmp Fast PCR Master Mix, 0.2µM WT forward primer, and 0.2µM
WT reverse primer with a 50µL reaction volume. Individual colonies from each transformation
were touched with a sterile tip then mixed into the reaction mixture. PCR was performed with
the following thermocycling conditions: Initial denaturation 94°C for 1 minute, and 30 cycles of
denaturation (5 seconds at 98°C) annealing (5 seconds at 55°C) and extension (6 seconds at
72°C). The PCR products were analyzed via gel electrophoresis by loading 5 μl of each reaction
onto a 1% agarose gel as shown in Figure 7C. Analytical gel electrophoresis of the PCR products
confirms successful transformations, as the bands in each lane fall between the 766 and 500 bp
mark correlating to a 618 bp product.
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Figure 7. Analytical DNA gel electrophoresis of Hsp27 mutant cloning procedure. A) DNA
electrophoresis gel of the site-directed mutagenesis S135F B) DNA electrophoresis gel of
processed plasmid pET-22b(+) and insert HspB1 WT gene before and after double digestion
with NdeI and XhoI. C) DNA electrophoresis gel of the colony PCR products that were
generated by using HspB1 WT primers.
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Chapter 3: Methodologies of Protein Expression and Purification of Hsp27 Protein
Variants
3.1 BACKGROUND
Protein expression is the mass production of recombinant protein by a host cellular
machinery. There are several expression systems available, prokaryotic in vivo expressions
systems will be explained in detail. Genetically recombinant plasmids are transformed into
prokaryotic in vivo expression systems to be placed under the control of the lac operon. The lac
operon is a naturally occurring region in the genome of enteric bacteria mainly used to regulate
lactose metabolism in the event of glucose shortages [94]. The lac operon contains three genes
that code for enzymes required for lactose metabolism such as beta-galactosidase; which is an
enzyme that hydrolyzes lactose into glucose and galactose thereby increasing the availability of
glucose to the bacteria [95].
To conserve energy and synthesize these proteins only when needed a repressor protein
known as the lac repressor binds the lac operon and inhibits any transcription and translation of
the genes. Increased concentrations of lactose signal a conformational change in the lac repressor
thus removing it from the operon and allowing RNA polymerases to bind and transcribe the genes
downstream [95]. Beta-galactosidase is eventually synthesized and begins to metabolize lactose,
increasing the concentration of glucose for the bacterial cell to use and decreasing the
concentration of lactose therefore allowing the lac repressor to bind the operon again [95].
This negative feedback loop controls the transcription and translation of lac operon
proteins to regulate their presence and energy expenditure. Researches have taken advantage of
this naturally occurring operon and have genetically engineered a gene coding for T7 RNA
polymerase into the lac operon [96]. Therefore, in the induction of protein expression of a culture
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of bacteria containing recombinant plasmid the presence of lactose will remove the lac repressor
which will be followed by transcription and translation of bacterial genes including T7 RNA
polymerase [96]. This polymerase will then bind the T7 promotor located on the recombinant
plasmid and will begin transcription of the gene placed downstream of the T7 promotor [96].
Through this process the protein of interest is synthesized but to produce substantial
amounts of protein the lac operon must be activated with a nonhydrolyzable version of lactose.
Although lactose can remove the lac repressor and initiate synthesis of genes downstream once
beta-galactosidase is produced it will hydrolyze lactose into its substituent monosaccharides and
in the absence of lactose the lac repressor will bind again and halt protein production [94, 96].
An analog of lactose such as isopropyl β-D-1-thiogalactopyranoside (IPTG) is used instead to
stimulate the lac operon because IPTG cannot be cleaved by beta-galactosidase therefore the lac
operon will be constitutively activated and production of the protein of interest will be at a
maximum [97].
It is necessary to extract target protein from the bacterial cells to analyze it and subject it
to subsequent experiments. Protein extraction can be accomplished by several means such as the
lysozyme freeze-thaw method [98]. This method of extraction involves lysing the cells by
exposure to chemical and physical means. The first step in this procedure involves resuspending
the cells in lysis buffer; the buffer will maintain the appropriate pH environment upon lysis of
the cells as to not denature the protein. The lysis buffer also places the cells in a hypotonic
environment facilitating cell swelling and rupture. The suspension is then treated with lysozyme,
an enzyme that digests the polysaccharide component of the bacterial cell wall [99]. Lysozyme is
a glycoside hydrolase that cleaves N-acetylglucosamine and N-acetylmuramic acid residues, the
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monomeric components making up the peptidoglycan layer of bacterial cells. The destruction of
this layer making up the bacterial wall facilitates in rupturing the cells and expelling its contents.
After lysozyme treatment the suspensions are subjected to several rounds of freezing and
thawing; this process further disrupts the cell wall by forcing the cell to swell and rupture.
During freezing the aqueous component of the suspension forms ice crystals that penetrate and
rupture the cell wall, the repeated freezing and thawing enhances the swelling and rupture
process effectively lysing most of the cells contained in the suspension. During lysis the
suspension grows increasingly viscous due to nucleic acids expulsion [99]. The genome and
other nucleic material of the cells becomes entangled with each other owing to the high viscosity
of the sample. Therefore, it is necessary to treat the sample with DNase 1, a nuclease that cleaves
DNA into substituent polynucleotides. DNase 1 treatment decreases the viscosity of the
suspension as the DNA is degraded thus dissolving the clumped mass of nucleic acids.
Resolving nucleic acids to shorter fragments interferes with the isolation and separation
of proteins in downstream chromatographic applications. Hence, the last step in the treatment of
bacterial extracts involves incubation with streptomycin which works to precipitate residual
nucleic acids ensuring minimal DNA and RNA contamination in subsequent applications. The
cell lysate is then centrifuged at high speed to pellet the unwanted cellular debris and nucleic
acids, the supernatant will contain a solution of a complex protein mixture (including the target
protein) that will need further processing.
It is good practice to add protease inhibitors to bacterial extracts as the process of cell
lysis not only releases the protein of interest, but potentially harmful proteins as well, known as
proteolytic enzymes such as proteases and phosphatases. These enzymes are tightly regulated in
intact cells and normally would not interfere with residing proteins but in the aftermath of cell
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lysis all enzymatic regulation is lost, and cleavage of target proteins is imminent. Protease
inhibitors work to deactivate proteolytic enzymes by reversible or irreversibly binding to
proteases or modifying their structure rendering them inactive. This extends the lifespan of target
proteins suspended in the cell lysate for following sample applications.
A pre-purification step is general applied to crude extracts of proteins to minimize the
number of contaminants present during chromatographic purification methods. Ammonium
sulfate precipitation is a commonly employed pre-purification method that works by
fractionating ranges of proteins based on their differences in solubility. Proteins that have polar
and charged residues coating their surfaces are solubilized in aqueous solutions; this works by a
network of electrostatic and hydrogen bonding interactions between protein and solvent. The
presence of minimal ions does little to deter these interactions, in fact they assist with
solubilizing the protein further by minimizing interactions between protein molecules in a
process known as salting in. However, as the salt concentration is increased the opposite effect
will take place, salting out.
At high enough salt concentrations, the least soluble molecule will precipitate out of
solution, in this case the proteins. This occurs because increasing the ionic medium increases the
number of molecules needed to be dissolved by the solvent therefore removing the number of
solvating molecules around the protein. Instead, the protein-protein interaction becomes more
favorable over the solvate-protein interaction as the available solvating molecules are decreased
and thus a protein precipitate forms [100]. Ammonium sulfate is the salt of choice for this
procedure because it is highly soluble in solution and has minimal interactions with proteins
avoiding protein denaturation [100]. The salt is usually added in a saturated solution or solid
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form, it is important to note that the ammonium sulfate should be added slowly allowing enough
tim`e to dissolve to not expose proteins to a high local concentration.
Proteins differ greatly in their makeup and as a result will have different relative
solubilities in solution, these differences can be exploited to fractionate proteins from each other.
A salt gradient is used to separate protein precipitates by increasing the concentration of
ammonium sulfate in a step wise manner. This means that proteins with lower solubilities will
precipitate out of solution at lower concentrations of ammonium sulfate while more soluble
proteins will require higher ionic strengths to be precipitated. At each gradient step, the solution
can be clarified, and the precipitate can be assayed for protein content while the supernatant can
be treated with a higher concentration of ammonium sulfate. The goal is to find the concentration
of ammonium sulfate that precipitates the target protein while excluding most of the
contaminants. Once this range is found the pellet containing the target protein is dissolved with
buffer, aliquoted, and is ready for subsequent steps in purification.
Fast performance liquid chromatography (FPLC) is a form of liquid chromatography
commonly used to separate mixtures of proteins in the attempt to purify a target protein. FPLCs
work by passing a solution through a column with affinities for certain characteristics of
proteins. These columns are cylindrical in shape and are filled with agarose beads; the beads can
vary in size or can be functionalized to attract certain proteins. The proteins will either have an
affinity for the column, the stationary phase, or the buffer it is dissolved in, the mobile phase.
Depending on which characteristic is exploited the protein will be attracted to the column or
remain in solution as it is passed through the column with a specific flow rate controlled by a
positive displacement pump. Passage through the column effectively separates proteins as most
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proteins exhibit unique properties and thus will have different affinities for the mobile and
stationary phase.
In a purification scheme several rounds of purification by different chromatography
columns may be needed to completely isolate a protein. Generally, ion-exchange
chromatography is the first column of choice due to this columns’ robust ability to handle crude
extract. Even after a pre-purification step the sample still contains thousands of contaminant
proteins and it is necessary to reduce this contamination before loading the mixture on a more
sensitive, polishing column. Although the ion-exchange columns can absorb high sample loads
and are more suitable as the first column in a multistep purification procedure. Ion-exchange
columns can be subdivided into cation-exchange and anion-exchange columns; the name implies
the target molecule the column will have an affinity for.
Columns contain beads that make up the matrix of the column, these beads are
functionalized with a molecule that has a charge opposite that of the target molecule; cation
exchange column resins are functionalized with negatively charged molecules and anion
exchange column resins are positively charged. Therefore, ion exchange columns purify proteins
based on their characteristic charge and it is necessary to manipulate the net surface charge of
proteins to maximize their absorption to the column. Proteins have a specific isoelectric point at
which they carry no net electrical charge at a certain pH, by altering the concentration of
hydronium and hydroxide ions the net charge of the protein can be manipulated. Proteins are
made of long chains of amino acids that each have unique properties that govern the protein to
assume a certain conformation in an aqueous environment, some amino acids contain ionizable
residues that will deprotonate at specific pHs based on their pKa values which is an expression to
denote the dissociation equilibrium of a molecule, in other words how acidic it is.
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Acidic residues have low pKas and thus will ionize in acidic mediums so long as the pH
is above its pKa, this is due to a shift in the acid dissociation equilibrium to afford protons. Basic
functional groups are weak acids with higher pKa values thus require a more basic medium to
lose a proton. This concept can be simplified to assume that at the isoelectric point the pH lies
exactly in the middle so that all the negatively charged ionized residues cancel out with the
positively charged ones. If the pH is raised above the isoelectric point this equilibrium will shift
and there will be a greater number of negatively charged residues leading to an overall net
negative charge. Conversely if the pH is lowered below the isoelectric point of the protein there
will be more positively charged residues owing to a net positive charge. The degree of positive
or negative charge can be increased by further increasing or lowering the pH, respectively. Once
the protein has been placed in a buffered solution at the appropriate pH it is ready to be loaded
onto on ion exchange column with a charge opposite to its net charge.
In preparation for protein loading, a column must be equilibrated with the solution the
protein is dissolved in, this is commonly called Buffer A known as the running buffer which is
contains a low ionic medium to allow the electrostatic interaction of protein to column resin. As
the protein is loaded onto the equilibrated column it will interact accordingly with the column of
choice; an anion exchange column is used to bind a net negatively charged protein and a cation
exchange column is used to target positively charged proteins. Once the protein is absorbed onto
the column a washing phase commences to push unbound proteins to the waste. To elute the
protein off the column a salt gradient is used to increase the concentration of ions passing
through the column in a linear fashion. The liquid chromatography system is hooked up to two
external solutions; one containing Buffer A and the other containing Buffer B, the elution buffer,
which has the same components as Buffer A plus a high concentration of salt such as 1M NaCl.
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The percentage of Buffer B passing through the column is gradually increased from 0%
to 100% by mixing in the corresponding proportions with Buffer A. The increased concentration
of ions will compete with the protein bound to the resin since the affinity of the ions to the
functionalized resin is usually stronger than the protein-resin interaction. Proteins with different
affinities to the column will elute at specific percentages of Buffer B (1M NaCl) and will pass
through two detectors that measure conductivity and absorbance. The conductivity measurement
gives the salt concentration that eluted the protein, and the absorbance measures the relative
amount of protein through absorption of UV at 280 nm by aromatic amino acids. These
measurements are correlated with the volume at which the protein eluted from the column and
fractionated.
Hydrophobic interaction chromatography targets proteins based on their degree of
hydrophobicity. These columns work by attracting hydrophobic proteins which is enhanced by
diluting the protein in a buffer with a high salt concentration. Usually, ammonium sulfate is used
at concentration from 0.5M to 2M. The higher the salt concentration the stronger the
hydrophobic interaction of the protein to column. To elute a protein from a hydrophobic
interaction column a decreasing linear salt gradient is applied. This means that the salt
concentration is steadily decreased by mixing proportions of Buffer A (which contains the high
salt concentration) and Buffer B (which is of low ionic strength). As the salt concentration
decreases the bound proteins will favor being solvated in the order according to their
hydrophobicity levels. This means that a less hydrophobic protein will require less of a decrease
in the ionic strength of the buffer to elute. Very hydrophobic proteins will require the ionic
strength of the buffer to be almost zero to elute from the column. In this way the hydrophobic
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interaction chromatography can be considered on opposite process to ion exchange
chromatography.
Gel filtration is used as a polishing column in multistep purification steps and as an
analytical tool to assess protein molecular sizes. Size exclusion columns are large columns
composed of a bed of porous beads of varying sizes that create a molecular sieve. This sieve
works to resolve proteins based on their size and three-dimensional shape; as proteins pass
through the column smaller globular proteins are better able to enter the pores within the beads,
with the smallest proteins passing through the smallest channels [101]. The route of smaller
proteins becomes longer as they diffuse deeper into the pores of the bed and therefore exit the
column at later elution volumes. Larger proteins are not able to enter this network of pores and
find the shortest path around the beads thus eluting earlier off the column. Size exclusion
columns can resolve a wide range of molecular sizes from 70 to 800 kDa and require only one
buffer solution for an isocratic elution. Size exclusion columns can only resolve small volume
samples as it is imperative the distance between like molecules is minimized. All proteins must
enter the column at roughly the same time, so their relative retention times are plausible.
3.2 MATERIALS AND METHODS
The Hsp27 proteins were tested for optimal expression levels followed by purification by
liquid chromatography by various chromatographic strategies.
3.2.1 Optimization of Protein Expression Levels of Hsp27 WT and Disease-Causing Mutants
Transformed cells were cultured in one liter of 2XTY media containing 16g of tryptone,
10g of yeast extraction, 5g NaCl, pH 7.5. Cells were grown to log phase indicative of an optical
density of 0.6 and induced via IPTG induction. Preliminary induction experiments began with
1mM IPTG for 2 hours at 37°C. To ensure protein expression SDS-PAGE analysis was
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performed to compare noninduced versus induced; 1mL samples were taken before and after
induction, pelleted, and the appropriate amounts were loaded onto a 12.5% SDS-PAGE (Figure
8A). The induced sample displayed a band that is not present in the uninduced sample with a
molecular size close to the 25kDa marker representing monomeric Hsp27 WT. Induction
experiments were repeated for the five mutant proteins and SDS-PAGE confirmed expression
comparable to that of Hsp27 WT. Later analysis revealed a need for higher expression levels.
IPTG concentration, temperature and incubation times were adjusted several times, eventually an
induction concentration of 0.1mM IPTG at 15°C for 18 hours produced acceptable amounts of
recombinant protein. Figure 8B shows an 18-hour induction period with 0.1 mM IPTG at 15°C,
samples were taken every 3 hours. Every progressing lane shows a band just above the 25kDa
mark increasing in intensity, at time 18 the maximum amount of protein is expressed. The
procedures mentioned were repeated for mutant proteins generating comparable results.
3.2.2 Cell Lysis and Ammonium Sulfate Precipitation
Following induction, the cells were pelleted in a Beckman centrifuge at 6000 g for 30
minutes. Pellets were resuspended in a lysis buffer composed of; 50mM Hepes NaOH-pH 7.5,
5mM EDTA, 1mM DTT. The suspension was treated with lysozyme at a final concentration of
1mg/mL for 4 hours at 4°C then exposed to 3 rounds of freezing and thawing. Positive lysis was
demonstrated from the suspension becoming increasingly viscous. The lysed extract was
incubated with DNase at a working concentration of 10µg/mL in conjunction with 60mM MgCl2
for 2 hours at 4°C with gentle agitation. Streptomycin sulfate was added to the mixture once
viscosity decreased and mixed for 30 minutes at 4°C. The suspension was centrifuged at 18,000
g for 30 minutes for clarification, the supernatant containing soluble protein was preserved for
further treatment with ammonium sulfate.
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The resulting mixture was treated with an ammonium sulfate gradient to target the ideal
precipitation range of Hsp27. A solution of saturated ammonium sulfate was added to the
mixture at a concentration of 30% with gentle agitation for 15 minutes at 4°C. The solution was
clarified, and the pellet was preserved while the resulting supernatant was treated with 40%
ammonium sulfate, the steps were repeated up until a concentration of 60% ammonium sulfate.
The four resulting pellets contributing to a different percentage of ammonium sulfate were
resuspended with water, the samples were then diluted accordingly and mixed with 4X loading
dye for run on a 12.5% SDS-PAGE as shown in Figure 8C.

Figure 8. Analytical SDS-PAGE of the Hsp27 protein prep procedure and optimization. A) Lane
1 molecular weight standard, lane 2 noninduced sample, lane 3 induced sample with band above
25kDa molecular marker B) Time lapse 12.5% SDS-PAGE of samples assayed every 3 hours,
lane 2 shows sample at time 0 C) Ammonium sulfate gradient of Hsp27 WT, lane 1 molecular
weight standard, lane 2 30% ammonium sulfate, lane 3 40%, lane 4 50%, lane 5 60%.
According to the ammonium sulfate gradient the sample treated with 30% ammonium sulfate
precipitated the most Hsp27 WT. Higher percentage treatments show effective separation of
Hsp27 WT from more soluble contaminants as seen in precipitates of 40%, 50%, and 60%
ammonium sulfate treatment. Following optimization, protein expression of Hsp27 WT and cell
lysis was repeated, the entire mixture was treated with 30% ammonium sulfate and the resulting
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precipitate was dissolved in 10mM Hepes pH 7.5, 5mM EDTA, and 1mM DTT. The solution
was aliquoted into 500µL samples and stored at -80°C. The methods described were repeated for
mutants R127W, S135F, R136W, and T151I. Mutant P182L remained in the insoluble fraction
after clarification of the cellular debris during cell lysis.
3.2.3 Purification of Hsp27 WT and Disease Mutants
3.2.3.1 Purification of Hsp27 Mutants by Anion Exchange and Size Exclusion
According to PhosphoSitePlus the isoelectric point of Hsp27 is 5.98, based on this value
an anion exchange column was used in the first phase of the purification of Hsp27 WT to keep
conditions at physiological pH. An ammonium sulfate prep was diluted in Buffer A (10mM
Hepes, 5mM EDTA, 1mM DTT) at a 1:10 ratio. Using a Bio-Rad NGC Chromatography system,
the sample was loaded onto two in series 5mL Hi Trap Q XL columns purchased from GE
Healthcare Life Sciences equilibrated with Buffer A. The protein was eluted from the columns
by a NaCl gradient generated by the system’s mixer by mixing Buffer A and Buffer B (10mM
Hepes, 5mM EDTA, 1mM DTT, 1M NaCl) in the appropriate proportions. As confirmed by
SDS-PAGE analysis Hsp27 WT elutes at a conductivity range between 10mS/cm – 16mS/cm
which parallels to 20 through 29% of Buffer B which is 200-290mM NaCl. Purification of
Hsp27 via anion exchange was repeated for the mutants R127W, S135F, R136W, and T151I.
The S135F and T151I mutant proteins exhibited similar elution profiles as the WT. The R127W
and R136W resulted in significantly lower yields and was later revealed to require multiple
rounds of purification.
A superose6increase size exclusion column purchased from GE Healthcare Life Sciences
was used in the second phase of the purification scheme of the Hsp27 proteins. Using an AKTA
purifier the column was equilibrated with 10mM Hepes buffer NaOH-pH 7.5 containing 5mM
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EDTA, 1mM DTT, and 100mM NaCl. Corresponding fractions from the previous anion
exchange run were concentrated using a 10,000 MW Vivaspin protein concentrator spin column
to a volume of approximately 500µL before loading onto the size exclusion column. The sample
was resolved by the column at a flow rate of 0.5 mL/min and eluted at a volume of around 14mL
indicating a size of approximately 530kDa. This procedure was repeated for the mutants S135F
and T151I.
The system was set to fractionate 0.5mL volumes and all the proteins eluted within a
2mL range. Hsp27 WT and mutant proteins T151I and S135F each exhibited the same behavior
during purification: a broad elution volume at around 14mLs. SDS-PAGE was used to analyze
the identity and purity of Hsp27 post-purification (Figure 9A). The bands correspond to
monomeric Hsp27 WT as the bands ran slightly above the 25kDa marker. The proteins were of
high purity and a lower band represents degradation of the target sample and not contaminants.
To confirm this, following purification Hsp27 WT was subjected to a time-lapse course with
samples collected every 24 hours to test for degradation over time as shown in Figure 9B. The
sample becomes increasingly degraded with each day; at the end of day 1 most of the protein is
intact with only minimal degradation but by day 4 more than half of the protein has been
degraded as the top band has decreased in intensity and the lower band has increased meaning
more sample has been cleaved into lower molecular weight fragments. Based on this data,
protein preparation and purification protocols were modified with the addition of an irreversible
serine protease inhibitor AEBSF purchased from Sigma. AEBSF was added to the cell lysis
buffer at a concentration of 1mM. In the last step of purification, following concentration of
appropriate fractions, AEBSF was added again at a concentration of 1mM. Figure 9C shows a
comparison between Hsp27 WT final purified samples with and without AEBSF inhibitor.
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Figure 9. Hsp27 inhibition of degradation optimization. A) Fractions B9-B12 run on 12.5% SDSPAGE B) Time lapse to test for degradation of Hsp27 WT protein, lanes 2 -4 represent sample
status at consecutive days starting with day 1 C)12.5% SDS-PAGE: lane 2 Hsp27 WT purified
sample prepared with 1mM AEBSF lane 4 Hsp27 WT purified sample without inhibitor.
Protein preparation and purification of mutants T151I and S135F protocols were also modified
by the addition of AEBSF inhibitor at the lysis stage and final sample stage during purification.
The serine protease inhibitor halted degradation of these protein samples with equivalent results
to the WT. The R136W and R127W proteins were also purified by these methods however it
required time-consuming repeated runs and still the yield was exceptionally low and challenging
to work with.
3.2.3.2 Purification of R136W and R127W by Anion Exchange Chromatography and
Hydrophobic Interaction
The R136W and R127W mutant proteins resulted in lower yields during gel filtration
step and multiple rounds of purifications were required to obtain sufficient yields. An alternative
purification scheme was developed for these two mutants. It was clear that the elution profile for
the oligomers of these proteins was substantially less than the WT, and according to the literature
these mutants were found to be in the monomeric state. We purified these alternate states of
R136W and R127W by anion exchange and hydrophobic interaction chromatography. First, the
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30% ammonium sulfate prep was diluted 1:10 in Buffer A. The solution was loaded on a Hi Trap
HP where it was found to not have any interaction with the column and was collected in the flow
through. This strategy allowed for increased purity as many contaminant proteins bound the
column. The flow through was concentrated and loaded onto the Superose6Increase and had an
elution profile of 18.58 mLs indicative of a monomer of Hsp27. However, the resulting SDSPAGE analysis confirmed the sample was not pure (Figure 10). The flow through was instead
concentrated and loaded onto a Hi Trap Butyl HP. The concentrate was diluted 1:30 in Buffer A
(10mM Hepes pH 7.4, 5mM EDTA, 2M Ammonium Sulfate) to promote hydrophobicity. A
reverse linear concentration gradient was applied where the concentration of the ammonium
sulfate was steadily decreased. The R136W protein was found to elute at a conductivity of
134mS/cm which indicates that the protein was strongly bound to the column and required
significant reduction in the ionic strength to reverse its reaction with the column (Figure 11). The
R127W monomer was also purified by this alternate strategy.

Figure 10. SDS-PAGE and chromatogram of the elution profile of R136W monomer.
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Figure 11. SDS-PAGE demonstrating resulting purity of the R136W monomer purified by
hydrophobic interaction chromatography.
3.2.4 Protein Prep and Purification of NTR and CTR mutants
The rationale for generating the CTR mutants was that purification of Hsp27 WT
revealed degradation. The serine protease inhibitor AEBSF was successful in inhibiting the
proteolysis of Hsp27 but in a purified sample we questioned what exactly was cleaving the
protein. In a purified sample it is possible that autoproteolysis was occurring which may indicate
that Hsp27 could regulate activity through this mechanism of cleavage. To locate the site of
cleavage we performed a time-lapsed degradation test at room temperature. After the sample was
completely degraded into a lower molecular weight product, we ran the sample on an SDSPAGE and cut out the band corresponding to the degraded product. We outsourced the sample
for sequencing via MALDI-TOF mass spectrometry which revealed that the Hsp27 protein was
being cleaved between residue positions 185 and 186. We mutated these residues to opposite
amino acids to discourage binding of the protease and generated the C-terminal deletion mutant
which mimics the degraded product.
The CTR mutants were prepped and purified according to the protocols created for the
WT. The CTR variants F185Y, E186Q, and double mutant were similar stored at room
temperature for several days to test for degradation. On day 5 the proteins were run on an SDS46

PAGE and the samples appeared to be degraded exactly like the WT (Figure 12). During cell
lysis the C-terminal deletion mutant remained in the insoluble fraction. This was attributed to the
removal of the C-terminal extension which is thought to provide solubility to the Hsp27 oligomer
complex.

Figure 12. SDS-PAGE analysis of time-course degradation experiment. From left to right:
F185Y day 1 and day5, E186Q day 1 and day 5, double mutant day 1 and day 5.
Later analysis reveals that the dimer is the more chaperone active unit but the oligomers
of Hsp27 do retain some chaperone activity. To explain this the NTR mutants were designed to
generate an Hsp27 protein that does not readily dissociate into smaller tetramers and dimers. The
single point mutations at the serine residues did not alter the behavior of Hsp27. The triple
mutant however was exceedingly difficult to clone by traditional cloning methods and ligation
free cloning. This construct was ordered and created from Genscript; we are currently studying
whether this protein has decreased chaperone activity.
3.3 PHOSPHORYLATION OF HSP27 BY CONSTITUTIVELY ACTIVE MAPKAPK2
During the stress response pathway Hsp27 is phosphorylated by the mitogen activated
protein kinase activated protein kinase 2 (MAPKAPK2). This phosphorylation event regulates a
47

shift in the equilibrium between oligomers and dimers of Hsp27. Therefore, Hsp27 exists in two
states as high molecular weight oligomers and smaller tetramers and dimers. Interestingly, the
literature is still somewhat divided on what the true chaperoning entity of Hsp27 is [102]. The
Hsp27 WT and disease-causing mutants where prepared in their oligomer and phosphorylated
states.
3.3.1 Preparation and Purification of MAPKAPK2
We designed and ordered codon optimized MAPKAPK2 with phosphomimicking
mutations at residues T222, S272, and T334 from Genscript. The threonine and serine residues
were replaced with glutamate residues to produce constitutively active kinase. The gene was
cloned into the pET-30a(+) plasmid that confers kanamycin resistance. The construct was then
transformed into competent BL21 (DE3) expression cells using kanamycin selection. The cells
were induced at 30°C for 4 hours with 0.2mM IPTG then sonicated at 25% amplitude with 1
second on and 3 seconds off time for a total of 2 minutes. The cellular debris was cleared
through centrifugation and the supernatant was treated with 20% ammonium sulfate to rid of
insoluble contaminants. The remaining supernatant was treated with an additional 20%
ammonium sulfate for a total of 40% ammonium sulfate treatment. The kinase was then loaded
onto a HiTrap SP HP column (GE Healthcare) at a rate of 3mL/min, a linear salt gradient was
applied, and fractions were collected at a conductivity of 35mS/cm. The fractions were pooled
and concentrated to a volume of ~300µL and loaded onto a Superose6Increase size exclusion
column and collected at an elution volume of ~18mL. Purity was confirmed by SDS-PAGE with
a single protein band at ~45kDa based on the precision plus protein dual colored standard (BioRad).
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Figure 13. Chromatogram of MAPKAPK2 loaded on a Superose6Increase. SDS-PAGE of
purified MAPKAPK2 confirming 45kDa
3.3.2 Phosphorylation of Hsp27
Following the protocol established by [46] each protein was phosphorylated by
MAPKAPK2 in vitro. Hsp27 WT at a final concentration of 0.7mg/mL was incubated with
MAPKAPK2 at 0.14mg/mL in a total reaction volume that accommodated over 1 microgram of
total Hsp27 WT protein. The reaction buffer contained 25mM Hepes-NaOH pH 7.5, 2mM DTT,
1mM AEBSF, and 20mM MgCl2. The reaction was initiated by the addition of 0.4µM ATP and
incubated at 25°C overnight. The reaction was terminated by the addition of 5mM EDTA and
analyzed by gel filtration (Superose6Increase 10/300 GL GE Healthcare), Urea-PAGE, dynamic
light scattering (Malvern Zetasizer Nano ZS), and negative-stained electron microscopy (JEOL
JEM 3200 FS). The procedure was repeated to generate the dimeric conformations of the mutant
proteins.

49

Figure 14. Confirmation of phosphorylated Hsp27. A) Size exclusion chromatogram highlighting
shift in elution profile of phosphorylated Hsp27 WT. Non-phosphorylated Hsp27 WT elutes at
13.57 mLs, following phosphorylation by the MAPKAPK2 the profile elution is shifted to 17.14
mLs indicative of a dimer of Hsp27. (Inset) Urea-PAGE run on (from left to right) Hsp27 WT,
T151I, S135F, R136W, R127W in their nonphosphorylated and phosphorylated forms. B)
Dynamic light scattering comparing Hsp27 WT nonphosphorylated and phosphorylated forms.
C) Transmission electron microscopy micrographs of nonphosphorylated (left) and
phosphorylated (right) Hsp27 WT.
Hsp27 WT nonphosphorylated (oligomer form) elutes early in the elution profile indicative of an
oligomer of Hsp27. The fractions were then pooled and concentrated and prepared for incubation
with MAPKAPK2. Following the phosphorylation procedure, the mixture is loaded on the same
column and a shift in the elution profile is observed from 13.57 mLs to 17.14 mLs, the third peak
at 20.65 mLs was confirmed to be ATP which absorbs strongly at 280nm.
The inset displays an image of a Urea-PAGE performed on the proteins in the
nonphosphorylated and phosphorylated forms. Urea-PAGE was chosen as it can distinguish
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phosphorylated proteins from nonphosphorylated proteins. During SDS-PAGE the proteins are
coated with the anionic detergent SDS and are made to be overall negatively charged where the
size of the protein is the only factor that contributes to its migration rate. The use of urea instead
of SDS still denatures the proteins but does not affect their overall charge therefore, proteins will
migrate based on their size and charge. Phosphorylated proteins can then be compared to
nonphosphorylated proteins as the introduction of the negatively charged phosphate groups will
substantially increase the rate of migration. As can be seen in Figure 14A inset, the phosphorylated
versions of Hsp27 WT and mutants migrate faster than their nonphosphorylated counterparts.
Interestingly the dimers of the mutant proteins R136W and R127W ran much faster than the dimer
of the WT; this can be explained by the loss of positive charge caused by the mutation from a
positively charged arginine to a neutral tryptophan causing the overall charge of the protein to be
more “negative”. Another noticeable difference was the slowed rate of migration of the S135F
dimer compared to the WT; although Urea-PAGE is used to detect differences in charge, the size
of the analyzed protein does influence its migration rate, therefore the decelerated S135F dimer
can perhaps be explained by the mutation from serine (105.09g/mol) to the much larger tryptophan
(165.19g/mol).
Lastly dissociation of the oligomers was confirmed by dynamic light scattering (DLS) and
negative-stained electron microscopy (EM). After purification, the proteins were analyzed by a
Malvern Zetasizer Nano ZS in a disposable cuvette at final concentration of 0.5mg/mL. The
hydrodynamic diameter of the WT oligomer was ~13nm (Figure 14B) and after phosphorylation
the diameter decreased to ~6.5nm confirming that phosphorylation induces the complex to
dissociate to smaller species. In addition, the samples were examined by negative-stained EM,
Figure 14C (left image) shows a clear distribution of randomly sized large spherical particles,

51

representing a heterogenous mixture of the WT oligomer. Phosphorylation of this sample results
in dissociation of those particles and a visual loss of the large spheres (right micrograph). The
dimer having a theoretical molecular weight of 45,656 Da falls short of the lower molecular size
limit (50,000 Da) required by EM imaging and thus further supports obtainment of the dimeric
form.
3.3.2.1 Co-Transformation with MAPKAPK2
The P182L mutant was not studied due to its characteristic nature to remain in the insoluble
fraction. An alternative approach was used to phosphorylate the P182L mutant so that solubility
can be maintained upon cell lysis. The P182L mutation causes Hsp27 to form large unstable
aggregates. If the P182L protein were dissociated before cell lysis it is possible to keep the protein
in the soluble state. Additionally due to low yield problems involving the R136W and R127W
mutant dimers the alternate procedure was also attempted. The plasmid constructs for P182L,
R136W, and R127W were each co-transformed with the MAPKAPK2 construct into competent
BL21(DE3) E. coli cells. The Hsp27 and kinase plasmids contained different selection antibiotic
markers, namely the Hsp27 mutant plasmids contained resistance to ampicillin and the
MAPKAPK2 plasmid confers resistance to kanamycin. Plates infused with both antibiotics were
used to select for colonies that only contained both constructs.
The cells were expressed, and the proteins were prepared for cell lysis and ammonium
sulfate treatment. The co-expression of the Hsp27 mutant proteins with MAPKAPK2 was
successful as both proteins were shown to be present during induction. Following clarification of
the cell lysate the Hsp27 mutant proteins were found in the cellular debris pellet as shown in
Figure 15. The supernatant was treated with 30% ammonium sulfate and the resulting
supernatant was revealed to contain soluble R136W and R127W protein along with kinase.
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Following ammonium sulfate treatment, the P182L protein was completely absent and so it was
deduced that either in vitro phosphorylation of P182L by MAPKAPK2 was unsuccessful in
solubilizing the mutant or the in vivo phosphorylation reaction did not take place. Following
purification, the R136W and R127W proteins that were co-expressed with the kinase did not
appear to have been phosphorylated in vivo as their elution profiles matched that of the WT
oligomer.

Figure 15. SDS-PAGE analysis of co-expressed protein preps of Hsp27 mutants and kinase. (A)
Hsp27 R127W and MAPKAPK2 co-expressed; lane 1: total induction, lane 2 cellular debris
pellet, lane 3: supernatant, lane 4 30% ammoniums sulfate pellet, lane 4: 40% ammonium sulfate
pellet. (B) Hsp27 R136W and MAPKAPK2 co-expressed; lane 1: total induction, lane 2 cellular
debris pellet, lane 3: supernatant, lane 4 30% ammoniums sulfate pellet, lane 4: 40% ammonium
sulfate pellet. (C) Hsp27 P182L and MAPKAPK2 co-expressed; lane 1: total induction, lane 2
cellular debris pellet, lane 3: supernatant, lane 4 30% ammoniums sulfate pellet, lane 4: 40%
ammonium sulfate pellet.
3.3.3 Purification of Phosphorylated Hsp27 proteins
To study the phosphorylated Hsp27 proteins further purification was required to isolate
Hsp27 from MAPKAPK2. The theoretical weight of a dimer of Hsp27 is 45,565 Da close to the
molecular weight of MAPKAPK2 45,568 Da. Following the phosphorylation reaction, the
mixture is loaded onto a Superose6Increase column where Hsp27 and MAPKAPK2 co-elute as
shown in Figure 16. To avoid MAPKAPK2 contamination in the Hsp27 samples, a new protocol
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was developed to isolate Hsp27 from the kinase. The reaction is diluted 1:30 in Kinase Buffer A
(10mM Hepes pH 6.7, 5mM EDTA) and loaded onto a Hi Trap SP HP column, the same column
used to purify MAPKAPK2. The kinase binds the column and the flow-through is fractionated
and collected as shown in Figure 16. The flow-through is then concentrated and loaded onto a Hi
Trap Desalting column to place the Hsp27 dimer into the appropriate buffer (10mM Hepes pH
7.4, 100mM NaCl, 1mM TCEP, 1mM AEBSF).

Figure 16. Purification of phosphorylated Hsp27. SDS-PAGE left lane displays purified
phosphorylated WT is contaminated by kinase; right lane depicts purified WT oligomer for
reference. Chromatogram of the fractionated Hsp27 dimer flow-through. The kinase is shown to
later elute at a high salt conductivity.
3.4 DISCUSSION
The mutant proteins T151I and S135F purifications produced the same results as the WT.
Only the P182L mutant did not reach the purification stage as it formed inclusion bodies during
the protein preparation stage after cell lysis. This was suspected to be caused by the mutation in
the IXI/V motif of the C-terminal domain. The central residue (182) of this conserved motif has
been mutated from a rigid proline to the more flexible leucine. This could further stabilize the
interaction between the C-terminal extension and the β4/β8 groove creating an interaction that
does readily dissociate leading to the formation of very large oligomers/aggregates [18, 56]. The
CTR/ACD weak interactions are crucial for not only mitigating substrate capture but also for
providing fluidity to the fluctuating oligomers of Hsp27, a feature noted to be critical for
polydisperse small heat shock proteins [18, 38, 56].
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Chapter 4 Functional Characterization
4.1 BACKGROUND
Hsp27 is a molecular chaperone that functions to prevent the aggregation of denaturing
substrate proteins. Small heat shock proteins are thought to be ubiquitous chaperones and can be
assayed for their chaperone activity using model substrates [22]. Some of the model substrates
commonly used for testing in vitro chaperone activity include malate dehydrogenase, alcohol
dehydrogenase, citrate synthase, α-glucoside, rhodanese, firefly luciferase, insulin, and
glyceraldehyde 3-phosphate dehydrogenase [22, 103]. Using these well-established aggregation
prevention assays the chaperone activity of several small heat shock proteins has been
characterized.
Surface plasmon resonance is an optical detection technique for studying labile free
biomolecular interactions in real time. Modern SPR systems are based on the detection scheme
known as the Kretschmann bond configuration [104, 105]. This system includes a light source
that is directed toward a metal surface that is situated between two mediums [104, 106]. The
light is polarized through a prism and when it hits at a certain angle the electrons in the metal are
excited and their movements are described as plasmon [106]. When a biomolecule encounters
the surface the plasmon cannot be achieved and there is a shift in the refractive index [104, 106].
This is measured by a detector as a dip in the intensity which is recorded as a response unit that
is dependent on how much of a molecule is binding.
An SPR instrument is typically made of a fluidics system, an optical system, and a sensor
chip [105]. The sensor chip contains the gold metal that is coated on a glass surface chip [105].
The chip can be functionalized with different molecules to facilitate different chemistries of
immobilizing a ligand to the sensor surface. The chip is placed on a flow cell with a
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microchannel that allows the continuous buffer system to have contact with the surface of the
sensor chip [107]. In this system various solutions can be injected and have contact with the
sensory surface. These include the ligand, analyte, regeneration buffer, and other necessary
solutions.
In an SPR experiment the ligand is first bound to the sensory surface through the capture
method of choice. These include carboxyl, amine, hydrophobic interactions, and tags. Any
remaining sights on the surface that did not bind the ligand are blocked to prevent nonspecific
binding events. The analyte is then diluted in the running buffer and passed over the sensor
surface to allow interaction time. The kinetics of any binding events that occur can be monitored
over time [105, 106]. As the analyte passes over the sensor, it will have an interaction with the
immobilized ligan, this is known as the association phase. The sensogram records this as an
increase in the response signal. As the analyte molecules continue to take up binding spots on the
immobilized ligands an equilibrium will eventually be reached as the rate of analyte molecules
coming off will equal the rate of molecules binding. This is observed as a plateau in the
sensogram. The fluidics system continuously passes buffer over the sensor surface so that the
next step the dissociation phase is recorded. This occurs as the analyte molecules are replaced by
the buffer system and the equilibrium shifts so that the analyte proteins unbind the ligand. The
association and dissociation constants can be derived from the binding and unbinding responses.
The ratio of these two constants gives the binding affinity of the biomolecules used in the
system.
The most reliable kinetic data is obtained by measuring the response of different analyte
concentrations. This is done by injecting analytes that are in a concentration range between 0.1
and 10 times the equilibrium constant (KD) of the system. The KD of a newly investigated system
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is typically not known and so a trial of different concentration ranges is optimized. This is done
by starting out with the lowest concentration of analyte and increasing the concentration until
evenly spaced curves are obtained. The dissociation phase for a system can be long, especially if
the interaction between the ligand and analyte is strong. To sample various concentrations of
analyte it is necessary to regenerate the sensor surface. The goal is to completely remove the
bound analyte without damaging the immobilized ligand. This can be achieved by injecting
solutions of either acidic basic or electrostatic mediums. In more difficult cases chaotropic
buffers or detergents can be injected to regenerate the ligand surface.
Finally, the data can be fit with binding models to obtain the kinetic information. A
binding model for kinetic interactions describes the binding reaction between two proteins in a
mathematical format. The reaction follows first order kinetics where L is the immobilized ligand,
A is the analyte, and LA represents the binding complex. L plus A is in equilibrium with LA
where the forward reaction defines the association constant, and the backwards reaction
represents the dissociation constant. The association rate constant measures the rate at which the
LA complex is forming. And the dissociation rate constant represents how fast this complex is
falling apart. Non-linear regression based on a 1 to 1 binding model is typically used to process
the SPR response curves. Tracedrawer is a fitting program that can calculate kinetic values for
multiple fitted curves.
4.2 AGGREGATION ASSAYS
The Hsp27 proteins were investigated for chaperoning capabilities in both their
oligomeric and dimeric conformations. The model substrates used were bovine α-lactalbumin
(14 kDa), porcine malate dehydrogenase (35 kDa), porcine citrate synthase (50 kDa), and firefly
luciferase (62 kDa). Each model substrate encompassed a specific molecular weight to expand an
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increasing molecular weight range from 14 – 62 kDa to study whether the size of the substrate
affected the chaperoning abilities. In addition, the method of denaturation/aggregation was
probed to discover if this altered the chaperoning pattern.
4.2.1 Chemical Denaturation of Model Substrates to Assess Chaperone Activity
4.2.1.1 DTT-Induced Aggregation of Alpha-Lactalbumin
The chemical reduction induced aggregation of α-lactalbumin chaperone activity assay
was adapted from [39]. α-lactalbumin (Sigma) aggregation was induced by reduction with DTT
in the absence and presence of Hsp27 WT and the four mutants T151I, S135F, R136W, R127W
each in their complexed and dissociated states. A 50µL mixture was prepared by incubating
0.85mg/mL α-lactalbumin (100mM sodium phosphate buffer, 300mM NaCl, 2mM EDTA pH
6.2) at 37°C. All components of the mixture, except DTT, were combined in a 10mm quartz
cuvette and incubated in the spectrophotometer at 37 °C for about 10 minutes. Once
thermostated the aggregation of α-lactalbumin was initiated by the addition of 35mM DTT.
Light scattering measurements were monitored by a Beckman DU 730 UV-Vis
spectrophotometer equipped with a temperature control unit at an emission wavelength of
360nm, this wavelength was chosen following a wavelength scan of the reaction prior and after
initiation of aggregation. The reaction conditions were repeated in the presence of oligomers and
dimers of Hsp27 WT and the mutants (10mM Hepes, 5mM EDTA, 1mM AEBSF pH 7.5) at a 1
to 1 molar ratio to α-lactalbumin. Bovine serum albumin and beta-lactoglobulin were used as
negative controls to rule out unspecific protein interactions.
4.2.1.2 Guanidinium HCL Induced Aggregation of Beta-Galactosidase
The protein β-galactosidase (Sigma) was diluted in 10mM Hepes-NaOH pH 7.5, 2mM
DTT. The reaction composed of β-galactosidase at a final concentration of 0.25mg/mL at a 1 to 1
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molar ratio to Hsp27. The reaction was thermostated at 3ۣ7°C in a 3mm quartz cuvette before the
addition of 0.54 M guanidinium hydrochloride. The addition of the denaturing agent induced
aggregation of β-galactosidase that was measured at 360nm. The reaction was repeated in the
presence of each Hsp27 proteins.
4.2.1.3 Hydrogen Peroxide Induced Aggregation of Aconitase
Chemically reduced denaturation of aconitase (Sigma) was extensively optimized.
Several methods of denaturation were trialed such as using urea, guanidinium hydrochloride, and
even changing the pH. Aconitase is a protein that is sensitive to oxidation and so the use of
hydrogen peroxide and ammonium persulfate was settled on. Aconitase was thermostated in a
3mm quartz cuvette at a final concentration of 0.11mg/mL in 10mM Hepes pH 7.4. Aggregation
was initiated by the addition of APS at 0.44 M. Under these conditions the light scattering
measured at 360nm reached 0.8 OD. The conditions were repeated in the presence of the Hsp27
proteins.
4.2.2 Thermal Denaturation of Model Substrates to Monitor Aggregation Activity
4.2.2.1 Thermal Aggregation of Malate Dehydrogenase
Lyophilized malate dehydrogenase (MDH) (Sigma) was dissolved in buffer composed of
10mM Hepes-NaOH pH 7.5 and 2mM DTT. The total amount of protein required to scatter light
to 1.0 unit was optimized. MDH was used at a final concentration of 0.317mg/mL at a 1:5 molar
ratio to Hsp27 (1.03mg/mL). The reaction was performed in a 100-microliter reaction volume in
a 3mm quartz cuvette preincubated at 42°C. In the control reaction MDH was incubated at the
concentration and temperature previously mentioned while turbidity measurements were
recorded in an Evolution 260 bio spectrophotometer equipped with a temperature control unit at
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360nm for one hour. The WT and mutant proteins were added in the presence of MDH in 5
independent reactions at 1 to 5 molar ratios of MDH to Hsp27.
4.2.2.2 Thermal Aggregation of Citrate Synthase
An ammonium sulfate suspension of citrate synthase was purchased from Sigma. This
solution was desalted in a 10mM Hepes buffer pH 7.5, 2mM DTT. The protein was concentrated
and used at a final concentration of 0.24 mg/mL. The control reaction was initiated by incubation
at 42°C. The reaction was monitored for 1 hour by an Evolution 260 bio spectrophotometer
equipped with a temperature control unit at 360nm. All experimental runs included incubation of
the model substrate at 1:5 molar ratio of Hsp27 to CS (WT, R127W, R136W, S135F, T151I).
Therefore, Hsp27 WT and each of the corresponding mutants were incubated at 0.529 mg/mL
(23.2 µM) with citrate synthase in 5 independent reactions.
4.2.2.3 Thermal Aggregation of Luciferase
The thermal induced aggregation of luciferase was monitored in the absence and presence
of Hsp27 WT and mutant proteins (R127W, R136W, S135F, T151I). Luciferase (Sigma) was
diluted to 0.25mg/mL in 10mM Hepes-NaOH pH 7.5, 2mM DTT in a final reaction volume of
60 microliters. The mixture was incubated at 42°C inducing aggregation of the model substrate
while turbidity measurements were recorded by an Evolution 260 bio spectrophotometer
equipped with a temperature control unit at 360nm for 20 minutes. The reaction was repeated in
the presence of Hsp27 WT and mutant proteins in 5 separate reactions at 1 to 5 molar ratios of
luciferase to Hsp27 (0.367 mg/mL).
4.3 SUBSTRATE TRANSFER ASSAYS
During the proteostasis pathway it is imperative that a small heat shock protein protects a
denaturing substrate from further denaturation and eventual irreversible aggregation. The next
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step is for the chaperone to transfer the substrate to either a chaperonin complex for refolding
and recycling back into the proteome or sent to the proteasome for degradation. Due to this we
sought to study the substrate transferring abilities of Hsp27. If the mutant proteins are not able to
efficiently and timely transfer its substrate to the next step in the proteostasis pathway, it could
have implications in disease progression.
4.3.1 Transfer of Model Substrate MDH to Mitochondrial Heat Shock Protein 60
In the thermal denaturation of the model substrate MDH in the presence of
phosphorylated Hsp27 WT the aggregation of MDH is prevented. We can conclude that
phosphorylated Hsp27 WT forms a stable complex with the denatured model substrate. Next, we
tested if phosphorylated Hsp27 WT can transfer the model substrate to the ATP dependent
chaperonin complex Hsp60/Hsp10. The chaperonin Hsp60 and co-chaperone Hsp10 were each
purified by anion exchange and size exclusion chromatography. Following purification by an
anion exchange the Hsp60 monomers were assembled into the tetradecameric complex and then
loaded onto a Superose6Increase. The Hsp10 co-chaperonin only required one round of
purification using a cation exchange column.
The substrate transfer assay was performed in a three-step process Table 6. The first step
involved performing the MDH aggregation assay as described earlier. Following an hour-long
incubation at 42°C the phosphorylated Hsp27 WT/denatured MDH complex was then incubated
with the chaperonin complex for refolding. The refolding reaction was set up as follows: a 15µL
volume containing 0.58 mg/mL of complexed Hsp60, 0.22mg/mL of Hsp10, and 0.018225
mg/mL of denatured MDH (previously incubated with Hsp27) was incubated for one hour at the
addition of 5mM ATP, the reaction buffer contained 10mM Tris, 100mM KCL, and 50mM
MgCl2. Following the incubation at 37°C, the temperature required for the chaperonin to refold a
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substrate, the reaction was then transferred to the third and final step. The refolding of denatured
MDH was monitored by using the commercially available kit Malate Dehydrogenase Assay Kit
from Sigma MAK196. All the assay components were mixed with 10 µLs of the refolding
reaction which equated to a final concentration of 0.003645 mg/mL of MDH, this was previously
tested to produce a signal close to 1.0 at 450 nm. The assay was monitored in a 96 well plate in
by a VarioSkan Lux Plate-reader. Malate Dehydrogenase is an NAD oxidoreductase that
catalyzes the conversion of malate into oxalacetate. The activity assay measures the activity of
the enzyme MDH in this catalysis by monitoring the production of NADH which is produced
during the conversion. Therefore, the activity of reactivated MDH is indirectly measured by the
assay kit.
Table 6. Stepwise protocol for substrate transfer assay

During the substrate transfer assay, we can assume that any signal produced during the
MDH activity assay is due to the denatured MDH that was first rescued by Hsp27 and then
transferred to Hsp60/Hsp10 for refolding and reactivation.
4.4 KINETIC ANALYSIS BY SURFACE PLASMON RESONANCE
The binding affinity values of phosphorylated Hsp27 proteins WT, T151I, and S135F to
the model substrate malate dehydrogenase were obtained through surface plasmon resonance
(SPR). An OpenSPR Benchtop SPR Instrument was used to collect binding kinetics and affinity
data. Each protein ligand was permanently immobilized to a carboxyl sensory chip using the
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Amine Coupling Kit – Proteins (Nicoya). The senor chip surface is first prepared with a pulse
injection of 80% isopropanol to remove any bubbles and a solution of acidic acid pH 2 to clean
the sensor surface. A mixture of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and Nhydroxysuccinimide (NHS) is loaded on the sensor surface to activate the carboxyl groups. The
ligands were then diluted to 0.05µg/µL in the Activation Buffer (Nicoya) which is a low pH
acetate buffer to enhance binding of the ligand to the carboxyl sensor chip surface through a preconcentration method. The protein ligand is then covalently coupled to the activated carboxyl
chip by a reaction between the protein primary amine groups and the N-hydroxysuccinimide
esters on the activated chip. The interaction time is enhanced with a 5-minute interaction time at
20 µL/min. Any remaining carboxyl groups on the sensor surface are then deactivated with a 1
M ethanolamine pH 8.0 blocking solution (Nicoya).
Once the protein ligands were immobilized to the sensory surface the analyte protein
concentrations were prepared in the running buffer (10mM Hepes pH 7.4). The ideal
concentration range of the MDH analyte was optimized for each Hsp27 protein ligand. MDH
was initially prepared at 1.28 µM and then serially diluted by half until a concentration of 0.01
µM was reached. To obtain the ideal concentration range of MDH analyte to each of the
phosphorylated Hsp27 proteins the serial dilutions were loaded by increasing concentration until
a signal response was achieved. The remaining concentrations were loaded to generate the 3 to 5
analyte response curves required for kinetic analysis. All the SPR experiments were performed at
42°C.
For the self-interaction experiments the Hsp27 proteins were immobilized as described
and each of the Hsp27 analyte proteins were prepared in running buffer at a concentration of
81.92 µM and then serially diluted by half to a concentration of 0.01 µM. The Hsp27 analyte
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proteins were flowed over the immobilized Hsp27 ligands until by increasing concentrations
until a proper response signal was achieved. The remaining analyte concentrations were loaded
to generate the required 3 to 5 analyte binding curves. The dissociation times for the ligand
analyte concentrations were very long and so a regeneration buffer was used after 5 minutes of
response time was recorded for this phase. The regeneration buffer removes the analyte and
prepares the ligand for the next analyte concentration. The regeneration buffer was loaded onto
the immobilized ligands before starting the analyte injection experiments to ensure the ligands
were not damaged. All response curves were buffer corrected before processing with
Tracedrawer software. A one-to-one binding model was used to fit the data sets.
4.4 RESULTS AND INTERPRETATION
4.4.1 Chaperone Activity
The aggregation assay with DTT-reduction induced α-lactalbumin in the absence or
presence of the Hsp27 proteins each in their respective conformations revealed varied results.
The WT in its oligomer conformation displays protective abilities towards aggregating αlactalbumin with 93% chaperone efficiency Figure 17A. After conversion to the dissociated form
the WT appears to lose its chaperoning capability and instead seems to aggravate the
precipitation process by exacerbating the light scattering to over 2.2 OD, above the detection
limit of the spectrophotometer. These results suggest that Hsp27 WT is an efficient chaperone to
the model substrate α-lactalbumin only in its complexed form. The mutant proteins T151I and
R127W had a similar effect as the WT with oligomeric protective abilities at 92.6% and 74%,
respectively and aggravation of precipitation in their dissociated states. Mutants S135F and
R136W proteins differed from the WT as oligomers where they were shown to exacerbate the
aggregation process, with the S135F reaction having the highest optical density at 2.79 (Figure
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17A). In the dimeric conformation these mutants did not afford any protection and displayed a
similar patter to all the other proteins in the dimeric forms. The only noticeable difference was
that the R136W dimer seems to delay the aggregation start by about 6 minutes (Figure 17B). To
explain this phenomenon there could be initial binding of the Hsp27 proteins to the denaturing αlactalbumin that induces a conformational change in the quaternary structure of the protein that is
unstable and precipitates.

Figure 17. Light scattering versus time of α-lactalbumin at 14.3 μM (0.85 mg/ml) after addition
of 35 mM DTT in the absence or presence of 60µM (1.4 mg/ml) Hsp27 WT, T151I, S135F,
R136W, or R127W. (A) WT and mutants are in their oligomer forms (B) WT and mutants are in
their dimer conformations.
The first thermally induced aggregation assay was performed with the model substrate
malate dehydrogenase (MDH) with a molecular weight of 35 kDa. In the control reaction
containing only MDH at a final concentration of 9 µM (0.317 mg/mL) the aggregated precipitate
scattered light to an optical density of 0.58. The WT and R136W oligomers displayed no
protective tendencies towards MDH as there was no appreciable difference between the
experimental runs and the control reaction (Figure 18A). The reaction performed in the presence
of complexed T151I reaches an OD above that of the control (1.11) indicating possible coprecipitation of the mutant protein with the model substrate MDH. The remaining mutant
proteins (S135F and R127W) display moderate chaperoning abilities in the prevention of MDH
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aggregation with protection abilities at 32% and 35%, respectively (Figure 18A). The dimers,
when assayed, all gained an increase in protective abilities for the substrate MDH (the complete
opposite effect for α-lactalbumin). The mutant proteins S135F, R136W, and R127W experienced
an increase in chaperoning ability of 99%, 97%, and 97%, respectively (Figure13B). The WT
and T151I proteins also gained effective chaperoning abilities measured at 85% and 86%,
respectively (Figure 18B).

Figure 18. Light scattering versus time of MDH at 9 μM (0.317 mg/ml) incubated at 42°C in the
absence or presence of 45 µM (1.03 mg/ml) Hsp27 WT, T151I, S135F, R136W, or R127W. (A)
WT and mutants are in their oligomer forms (B) WT and mutants are in their dimer
conformations.
The control reaction containing approximately 4µM of CS scattered light up to an OD of
around 1. This reaction performed in the presence of oligomeric Hsp27 WT at a molar
concentration of 1 CS molecule to 5 monomeric Hsp27 yielded protection of the model substrate
demonstrated with a decrease in turbidity of the sample to 0.4 in comparison to the control
(59%). The mutant protein T151I incubated with citrate synthase under the same conditions and
molar ratio as the WT protein afforded more protection to the substrate with a decrease in
aggregation from 1 to just above 0.2 light scattering units (77%). The other three mutant
proteins; S135F, R136W, and R127W assayed under equivalent conditions provided even further
protection for the substrate CS with protection levels of 88%, 92%, and 89%, respectively
(Figure 19). These results are in direct opposition with the protection patterns observed for the
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reduction induced aggregation of the substrate α-lactalbumin with the WT and T151I oligomer
proteins offering more protection for α-lactalbumin than the mutant proteins R127W, R136W,
and S135F. The assay was repeated for all five proteins in their dimeric conformation following
incubation with MAPKAPK2. (Figure 19B) Hsp27 WT in its dimeric conformation gains an
increase in chaperoning ability compared to its complex form with an increase in protection from
59% in the case of the oligomer to 98% for the dimer. Mutant protein T151I, S135F, R136W,
and R127W demonstrate a similar pattern to the WT with an increase in chaperoning abilities
upon phosphorylation at protection percentages of 95, 99, 98, and 98, respectively.

Figure 19. Light scattering versus time of citrate synthase at 4 μM (0.24 mg/ml) incubated at
42°C in the absence or presence of 23.2 µM (0.529 mg/ml) Hsp27 WT, T151I, S135F, R136W,
or R127W. (A) WT and mutants are in their oligomer forms (B) WT and mutants are in their
dimer conformations.
The final substrate used with the highest molecular weight of 62kDa was luciferase. The
control reaction containing luciferase at a final concentration of 4.03 µM (0.25mg/mL) following
incubation at 42°C scattered light up to an optical density of 0.67. When the reaction was
performed in the presence of Hsp27 WT the aggregation was exacerbated with a recording of
0.92 light scattering units meaning the protein provided no protective abilities and instead
precipitated alongside the substrate. The oligomer R127W displayed the closest results to the
WT with a final light scattering reading of 0.91 at 10 minutes. Mutant proteins T151I and
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R136W intensified the precipitation of the reaction with ODs recorded at 1.17 and 1.19,
respectively (Figure 20A). These proteins like the WT offered no prevention for the aggregation
of luciferase but appeared more insoluble than the WT/LUC complex. Only mutant S135F did
not worsen the turbidity reading of the reaction in comparison to the control, meaning this
protein did not co-precipitate with luciferase instead oligomer S135F appeared to have chaperone
abilities against luciferase aggregation measured at 70% (Figure 20A). The assayed
phosphorylated proteins demonstrated comparable results to other thermally induced aggregation
assays with a substantial increase in protection for LUC. The WT and T151I dimers went from
co-aggregating with LUC to providing considerable protection against aggregation with
percentages of 70% and 78%, respectively (Figure 20B). The remaining mutant dimers S135F,
R136W, R127W displayed the greatest protection for this substrate with negative protection
values as oligomers (R136W -78% and R127W -36%) increasing to 93% and 99% as dimers.
Interestingly, only the S135F mutant protein in both its conformations had the ability to protect
luciferase with the oligomer offering 70% protection and the dimer marginally increasing to 97%
protection ability.

Figure 20. Light scattering versus time of luciferase at 4.03 μM (0.25 mg/ml) incubated at 42°C
in the absence or presence of 16.1 µM (0.367 mg/ml) Hsp27 WT, T151I, S135F, R136W, or
R127W. (A) WT and mutants are in their oligomer forms (B) WT and mutants are in their dimer
conformations.
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The R136W and R127W mutants purified int their monomeric forms did not have
chaperone protection for the four model substrates (data summarized in Figure 31). In fact, these
proteins resulted in aggravation of precipitation with light scattering intensities measuring above
the control. Protection percentages from all the aggregation assays were obtained by comparing
the difference in light scattering of the experimental run with the light scattering value of the
control (absent of Hsp27). Assays were performed either in duplicates or triplicates, but the
values displayed are not the mean of the repeated runs, this was due to the fact that each time the
assay was performed the control reactions provided different results in terms of the light
scattering values sometimes being very different. The final mean protection values were graphed
for comparison purposes (Figure 31).
4.4.2 Transfer of Model Substrate MDH from Hsp27 to Mitochondrial Hsp60/Hsp10
Chaperonin for Refolding
To test for the ability of Hsp27 WT dimer to transfer the model substrate MDH to the
Hsp60/Hsp10 chaperonin complex several ratios were tested. The concentration of MDH was
held constant at 0.3mg/mL and the molar ratio of Hsp27 WT dimer was increased incrementally
by 1. Molar ratios from 1:1 to 1:23 were trialed to test what was the highest ratio of Hsp27 WT
necessary to transfer the model substrate to the chaperonin. The signal began to overlap at a
molar ratio of 1 MDH to 19 Hsp27 and beyond. Although the signal reached 3.0 OD which is the
detector limit of the plate reader. Each independent reaction was controlled for by a reaction that
contained all components of the reaction except the chaperonin complex. These control reactions
produced negligible signal compared to the experimental reactions. Additional controls such as
the positive and negative controls were also set up. The positive control contains the chaperonin
complex incubated with native MDH. The negative control consists of denatured MDH without
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the incubation with the chaperonin. A last control was setup containing the phosphorylated
Hsp27 protein incubated with the chaperonin but without any denatured substrate.
The substrate transfer assay with Hsp27 WT was repeated for molar ratios 1:1 to 1:8.
Each time the concentration of phosphorylated Hsp27 WT is increased by one, the signal
increases as shown in (Figure 21). The assay performed with mutant Hsp27 proteins T151I and
S135F also produced similar results. At ratios of 1 denatured MDH to 8 phosphorylated Hsp27,
the signal of reactivated MDH reaches that of the positive control as shown in Figures 22 and 23.
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Figure 21. Malate dehydrogenase activity assay used to study the substrate transferring ability of
Hsp27 WT. Increasing ratios from 1:1 to 1:8 of MDH to phosphorylated Hsp27 WT protein were
incubated at 42°C followed by incubation with the Hsp60/Hsp10 chaperonin system at 37°C for
reactivation of MDH. The curves represent the enzymatic activity of reactivated MDH at 450nm.

Figure 22. Malate dehydrogenase activity assay used to study the substrate transferring ability of
Hsp27 T151I. Increasing ratios from 1:1 to 1:8 of MDH to phosphorylated T151I protein were
incubated at 42°C followed by incubation with the Hsp60/Hsp10 chaperonin system at 37°C for
reactivation of MDH. The curves represent the enzymatic activity of reactivated MDH at 450nm.
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Figure 23. Malate dehydrogenase activity assay used to study the substrate transferring ability of
Hsp27 S135F. Increasing ratios from 1:1 to 1:8 of MDH to phosphorylated S135F protein were
incubated at 42°C followed by incubation with the Hsp60/Hsp10 chaperonin system at 37°C for
reactivation of MDH. The curves represent the enzymatic activity of reactivated MDH at 450nm.
4.4.3 Kinetic Analysis of Hsp27 Binding Affinities to Model Substrate and Self-Interactions
The phosphorylated Hsp27 WT protein was immobilized on the surface of a carboxyl
sensor chip using the amine-coupling chemistry kit (Nicoya). The MDH analyte was diluted in
the running buffer (10mM Hepes pH 7.4) to a concentration of 1.28 µM. Performing serial
dilutions a concentration range of 0.01, 0.02, 0.04, 0.08, 0.16, 0.32, 0.64, and 1.28µM was
established. Only 3 to 5 analyte runs were required to produce reliable kinetic data however the
concentration range of the analyte MDH sufficient to produce spread out curves was not known.
Therefore, the lowest concentration of analyte was injected until there was a response signal. The
analyte concentration range of 0.08, 0.16, 0.32, 0.64µM produced the best curves Figure 24.
Each analyte concentration was flowed over the ligand surface at a flow rate of 20µl/min for five
minutes to generate the association response and the response date was collected for an
additional 7 minutes to ensure that at least 5% dissociation of the analyte. The response curves
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were fitted with Tracedrawer using a 1 to 1 binding model. The resulting equilibrium constant
(KD) for the phosphorylated Hsp27 WT ligand and model substrate MDH analyte was 0.017µM
which indicates a strong binding interaction.

Figure 24. SPR sensogram: interaction between MDH analyte and phosphorylated Hsp27 WT.
MDH analyte at concentrations of 0.08µM (red), 0.160µM (green), 0.320µM (cyan), 0.640µM
(turquoise) were flowed over phosphorylated Hsp27 WT covantly captured to a carboxyl sensory
chip at 42°C. The data is fitted using a 1 to 1 binding model, fitted curves are overlapped in
black.
The equilibrium constants for T151I and S135F phosphorylated proteins to the MDH
model substrate were obtained by similar procedure. An analyte concentration range of 0.16,
0.32, 0.48 0.64, 0.94µM was used for the T151I interaction (Figure 25). These concentrations
were adjusted in real time to evenly space out the response curves. The analyte concentrations
used for the immobilized S135F mutant were 0.08, 0.16, .32, 0.64, and 1.28µM (Figure 26). The
resulting KDs were 0.106µM for the phosphorylated T151I/MDH system and 0.091µM for the
S135F/MDH system (Table 7). The phosphorylated WT/MDH system demonstrates the strongest
binding constant indicating that phosphorylated Hsp27 WT binds denatured MDH strongly as
also supported by the need of a regeneration buffer. The phosphorylated S135F/MDH system
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also displays a strong binding interaction and the affinity of phosphorylated T151I to MDH is
only slightly less.

Figure 25. SPR sensogram: interaction between MDH analyte and phosphorylated Hsp27 T151I.
MDH analyte at concentrations of 0.160µM (yellow), 0.320µM (magenta), 0.48µM (purple)
0.640µM (turquoise), 940µM (gray) were flowed over phosphorylated Hsp27 T151I covantly
captured to a carboxyl sensory chip at 42°C. The data is fitted using a 1 to 1 binding model,
fitted curves are overlapped in black.

Figure 26. SPR sensogram: interaction between MDH analyte and phosphorylated Hsp27 S135F.
MDH analyte at concentrations of 0.08µM (lime green), 0.160µM (blue), 0.320µM (black),
0.640µM (gray), 1.28µM (turquoise) were flowed over phosphorylated S135F covantly captured
to a carboxyl sensory chip at 42°C. The data is fitted using a 1 to 1 binding model, fitted curves
are overlapped in black.
These data are consistent with the aggregation assays that demonstrate the WT and two
mutant proteins in their phosphorylated forms are good chaperones for the model substrate
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MDH. As demonstrated in the substrate transfer assays the Hsp27 proteins are sufficient in either
transferring or releasing substrate as monitored by the reactivation of the MDH substrate by the
Hsp60/Hsp10 chaperonin complex. The SPR analyses do not display a discrepancy in the
binding affinities of the Hsp27 mutants to bind and protect MDH. Although the affinity of
phosphorylated Hsp27 to model substrate is relatively strong the ability to release or transfer
substrate persists. The self-interactions of the phosphorylated Hsp27 proteins were investigated
to understand if the method of release of substrate results from the competition of the propensity
of Hsp27 to form self-interactions.
The phosphorylated WT was covantly immobilized to a carboxyl sensory by the same
methods described. The phosphorylated WT was diluted to a concentration of 40.96µM in the
running buffer. Serial dilutions were used to obtain an analyte concentration range of 1.28, 5.12,
10.24, 20.48, and 40.96µM. Figure 27 shows the fitted SPR responses that gave an equilibrium
constant of 3µM. The self-interactions of Hsp27 WT are significantly less than its binding
affinity to the denatured model substate MDH. This could explain why the chaperone has potent
chaperoning abilities in the protection of the thermally denatured model substrate. The selfinteractions for the dimers of T151I and S135F were also obtained. The phosphorylated T151I
mutant proteins has a KD of 34.6µM which is a low binding affinity. Interestingly, this does not
correlate with increased chaperone activity by the T151I mutant dimer. This could simply arise
from the sensitivity level of our methods of assaying.
Lastly and most notably the phosphorylated S135F self-interactions are very strong with
a KD value of 0.0154µM. This equilibrium constant is almost 200 times stronger than the WT
self-interactions. Although we do not see a decrease in the chaperoning activity of the S135F
protein with the model substrates chosen the extremely high self-interactions could potentially
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outcompete binding with other in vivo substrates. In addition, we also obtained the binding
affinity for the self-interactions for the WT oligomer. This form of Hsp27 does not protect the
model substrate MDH from aggregation and so the SPR analyses was only performed on its selfinteractions. The WT Oligomer/WT Oligomer self-interactions result in an equilibrium constant
of 0.385µM, a substantial increase from the low binding of the phosphorylated WT selfinteractions. This could potentially explain why the chaperone in its oligomer form is not able to
protect MDH as its self-interactions overcome any binding to MDH. The self-interactions for the
oligomers of T151I and S135F remain to be investigated.

Figure 27. SPR sensogram: interaction between phosphorylated Hsp27 WT and phosphorylated
Hsp27 WT. Phosphorylated WT analyte concentrations of 1.28µM (dark green), 5.12µM (red),
10.24µM (yellow), 20.48µM (magenta), 40.96µM (turquoise) were flowed over phosphorylated
Hsp27 WT covantly captured to a carboxyl sensory chip at 42°C. The data is fitted using a 1 to 1
binding model, fitted curves are overlapped in black.
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Figure 28. SPR sensogram: interaction between phosphorylated Hsp27 T151I and
phosphorylated Hsp27 T151I. Phosphorylated T151I analyte concentrations of 10.24µM
(purple), 20.48µM (lime green), 40.96µM (pink), 81.29µM (red) were flowed over
phosphorylated Hsp27 T151I covantly captured to a carboxyl sensory chip at 42°C. The data is
fitted using a 1 to 1 binding model, fitted curves are overlapped in black.
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Figure 29. SPR sensogram: interaction between phosphorylated Hsp27 S135F and
phosphorylated Hsp27 S135F. Phosphorylated S135F analyte concentrations of 0.04µM (lime
green), 0.08µM (cyan), 0.160µM (orange), 0.320µM (green), 0.640µM (magenta) were flowed
over phosphorylated Hsp27 S135F covantly captured to a carboxyl sensory chip at 42°C. The
data is fitted using a 1 to 1 binding model, fitted curves are overlapped in black.

Figure 30. SPR sensogram: interaction between Hsp27 WT oligomer and Hsp27 WT oligomer.
Hsp27 WT oligomer analyte concentrations of 0.16µM (green), 0.36µM (magenta), 0.64µM
(purple), 1.28µM (gray), 25.6µM (black) were flowed over Hsp27 WT oligomer covantly
captured to a carboxyl sensory chip at 42°C. The data is fitted using a 1 to 1 binding model,
fitted curves are overlapped in black.
4.5 DISCUSSION
In summary it is evident that the Hsp27 proteins have a higher affinity towards thermally
denatured substrates whether in their complexed or dissociated states. This correlates with
reports that Hsp27 is active at higher temperatures, causing an increase in subunit exchange
which leads to the conclusion that the dimer of Hsp27 is the more chaperone active conformation
(in terms of thermally denaturing substrates). The reason that most of the oligomers also retain
significant amounts of chaperone function could be attributed to subunit exchange between the
oligomers. Testing the abilities of the oligomer comes with limits since there is continuous
subunit exchange and technically a smaller population of dimers always exist in the “oligomer
conformation” supporting the notion that the dimer is the true chaperone active form.
78

In addition, there is a clear trend of the three mutants with substitutions in the dimer
interface (S135F, R136W, and R127W) always displaying slightly higher chaperone activity
than the WT during the thermal aggregation assays and the T151I protein with its mutation near
the β4/β8 groove continuously displaying similar results to the WT. These findings suggest that
the mutations in the dimer interface groove of Hsp27 may result in a “toxic gain of function” and
although the differences are not staggering these subtle changes may have a larger effect in vivo
with physiological substrates implying that Hsp27 with mutations in the dimer interface groove
may unnecessarily bind proteins causing a loss of function of the bound substrate. To imply that
the dimer conformation is the true chaperoning unit would suggest that proteins in their
unphosphorylated states should also retain some chaperoning ability. However, this is only true
for citrate synthase where all the proteins in their complexed states can protect CS but for MDH
and LUC the WT oligomer cannot protect these thermally denatured substrates.
This could be explained by a molecular weight chaperoning range that Hsp27 is restricted
to, even though there are many reports that Hsp27 is a promiscuous chaperone. It could be the
case that a dimer of Hsp27 (still present in the oligomer state) has higher affinity for a denaturing
substrate closer to its own dimeric molecular weight (45kDa) which is the case with monomeric
CS (50kDa). This limiting factor may only take effect when Hsp27 is in its oligomer state where
there is shortage of available dimers however in its phosphorylated state there is an abundance of
dimers that could overcome this molecular weight cut-off effect and instead display an avidity
effect where multiple dimers can bind one denaturing substrate molecule at a time.
The aggregation assay employed with the chemically induced model substrate αlactalbumin displays results with a staggering opposition to the other three thermally denatured
assays. As dimers none of the proteins, WT, or mutant, can protect α-lactalbumin this can be
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explained by two possible reasons. This assay was performed at the biological temperature of
37°C instead of at the physiological heat shock temperature of 42°C (like the other assays).
There are multiple accounts in the literature stating that an increase in temperature parallels with
an increase in chaperoning capabilities. Another probable prospect may have to do with the
chaperone active region of Hsp27 towards α-lactalbumin; the hydrophobic N-terminal domain
may be the ideal region for denatured α-lactalbumin to bind and when phosphorylation
introduces negative charges the repulsion may overcome the weak interaction between Hsp27
NTR and the small molecular weight substrate. This further signifying that the larger the
denatured substrate is, the more opportunity there is for hydrophobic interactions between the
NTR and the substrate that can overcome the negative charge effect. As for the oligomers of
S135F and R136W severely exaggerating the aggregation effect it may have something to do
with both these residues (located in the extended β-strands 6+7) being mutated to large
hydrophobic/aromatic residues that compromise the dimer interface and somehow lead to large
irreversible aggregates when bound specifically with a chemically denatured model substrate.
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Figure 31. Aggregation assays with the oligomers and the four model substrates organized for
comparison. MDH Substrate: Multiple paired T-test: WT Oligomer vs. T151I Oligomer: P =
0.306, WT Oligomer vs. S135F Oligomer: P = 0.010, WT Oligomer vs. R136W Oligomer: P =
0.741, WT Oligomer vs. R127W Oligomer: P = 0.014, WT Oligomer vs. WT Phosphorylated: P
= 0.007, WT Phosphorylated vs. T151I Phosphorylated: P = 0.794, WT Phosphorylated vs.
S135F Phosphorylated: P = 0.833, WT Phosphorylated vs. R136W Phosphorylated: P = 0.266,
WT Phosphorylated vs. R127W Phosphorylated: P = 0.294, WT Phosphorylated vs. R136W
Monomer: P = 0.007, WT Phosphorylated vs. R127W Monomer: P = 0.008, n=3 for each assay.
CS Substrate: Multiple paired T-test: WT Oligomer vs. T151I Oligomer: P = 0.130, WT
Oligomer vs. S135F Oligomer: P = 0.011, WT Oligomer vs. R136W Oligomer: P = 0.024, WT
Oligomer vs. R127W Oligomer: P = 0.034, WT Oligomer vs. WT Phosphorylated: P = 0.113,
WT Phosphorylated vs. T151I Phosphorylated: P = 0.702, WT Phosphorylated vs. S135F
Phosphorylated: P = 0.974, WT Phosphorylated vs. R136W Phosphorylated: P = 0.400, WT
Phosphorylated vs. R127W Phosphorylated: P = 0.393, WT Phosphorylated vs. R136W
Monomer: P = 0.004, WT Phosphorylated vs. R127W Monomer: P = 0.015, n=3 for each assay.
LUC Substrate: Multiple paired T-test: WT Oligomer vs. T151I Oligomer: P = 0.028, WT
Oligomer vs. S135F Oligomer: P = 0.001, WT Oligomer vs. R136W Oligomer: P = 0.055, WT
Oligomer vs. R127W Oligomer: P = 0.470, WT Oligomer vs. WT Phosphorylated: P < 0.001,
WT Phosphorylated vs. T151I Phosphorylated: P = 0.424, WT Phosphorylated vs. S135F
Phosphorylated: P = 0.025, WT Phosphorylated vs. R136W Phosphorylated: P = 0.019, WT
Phosphorylated vs. R127W Phosphorylated: P = 0.015, WT Phosphorylated vs. R136W
Monomer: P = 0.007, WT Phosphorylated vs. R127W Monomer: P = 0.011, n=3 for each assay.
α-lac substrate: Multiple paired T-test: WT Oligomer vs. T151I Oligomer: P = 0.634, WT
Oligomer vs. S135F Oligomer: P = 0.002, WT Oligomer vs. R136W Oligomer: P = < 0.001, WT
Oligomer vs. R127W Oligomer: P = 0.021, WT Oligomer vs. WT Phosphorylated: P < 0.001,
WT Phosphorylated vs. T151I Phosphorylated: P = 0.436, WT Phosphorylated vs. S135F
Phosphorylated: P = 0.145, WT Phosphorylated vs. R136W Phosphorylated: P = 0.801, WT
Phosphorylated vs. R127W Phosphorylated: P = 0.549, WT Phosphorylated vs. R136W
Monomer: P = 0.002, WT Phosphorylated vs. R127W Monomer: P = 0.006, n=3 for each assay.
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The aggregation assays demonstrated that the disease-mutants do not cause a deficit in
chaperoning activity. Disease progression may occur through a toxic gain of function mechanism
however the substrate transferring ability was additionally probed to test whether the mutant
proteins form an irreversible or prolonged interaction with their substrate. As a molecular
chaperone Hsp27 acts as a holdase, forming a stable interaction with a partially denatured
substrate, the next step of transferring the substrate within the proteostasis pathway is crucial. A
small heat shock protein that has an ill-timed interaction with its substrate could also be cause for
disease progression. Firstly, the client protein is not recycled into the proteome and second the
protective abilities of Hsp27 are occupied, leaving other denaturing client proteins at risk for
irreversible aggregation.
To explore this notion a substrate transfer assay was designed to test the substrate
transferring abilities of Hsp27. The model substrate MDH was used as this aggregation assay
produced results where both mutant proteins T151I and S135F prevented the aggregation of
MDH. The chaperonin Hsp60/Hsp10 was used as this complex has been previously shown in our
lab to refold denatured MDH. If the mutant proteins have delayed or altered transferring abilities,
that are measured by the amount of renatured MDH, it could be indicative of disease mechanism.
At a 1:1 molar ratio of phosphorylated Hsp27 to denatured MDH the light scattering signal is
completely suppressed. Under our aggregation prevention assay this implies that one Hsp27
molecule per one MDH protein is sufficient to prevent aggregation. When this complex is
incubated with the Hsp60/Hsp10 chaperone the refolding signal of MDH is minimally increased.
The ratio of Hsp27 was then incrementally increased to produce the signal indicative of complete
renaturation of the entire MDH population. This implies that more Hsp27 chaperone is required
to completely protect all the MDH sample from denaturation however, the population that it does
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protect is sufficient to prevent aggregation. This simply means that the concentration required for
MDH to aggregate is quite high and does not mean that all the sample is not denatured.
Therefore, the increase in renaturation signal is partially explained by the increased presence of
Hsp27.
The substrate transfer assays demonstrate that Hsp27 can either transfer or in the very
least release its bound substrate. Transferring of the model substrate MDH to the Hsp60/Hsp10
chaperonin complex is plausible as this protein plays an active role in other refolding
mechanisms. However, it may be more likely that Hsp27 relies on a mechanism that involves
release of its substrate. This is supported by the observance that an increase in the Hsp27
chaperone concentration to the denaturing model substrate results in an increase in reactivation.
Previous studies have confirmed that the ACD of Hsp27 is a groove presenting region for the
NTR and CTR to bind. The transient contacts made by these regions is a means to regulate
activity. This competition within the regions to continuously bind the ACD is what drives the
availability of the NTR to bind a substrate.
The competition between substrate and available NTR and CTR from other Hsp27
proteins may drive substrate release where the Hsp60/Hsp10 then has an opportunity to bind and
refold the denatured model substrate. Therefore, the increased availability of chaperone
outcompetes the interaction with the substrate. Instead of another Hsp27 protein binding the
substrate the chaperonin complex is present to refold the substrate and the affinity of Hsp27 for
the substrate is minimized. This leaves more opportunity for Hsp27 to continuously outcompete
the substrate for self-interactions and drives the equilibrium of Hsp27/substrate complexes to
Hsp60/Hsp10 for refolding.
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To test whether the mutants may have a deficit in their substrate transferring abilities the
experimental conditions were reproduced at the same molar ratios. Figure 32 shows that the
mutants T151I and S135F display the same trend of protection and substrate transferring ability
as the WT. The T151I protein does appear to have increased substrate transferring ability as
measured by refolding and the S135F protein does seem to have slightly less transferring activity
however the data were not significantly different from the WT. To test whether these differences
are plausible we measured the binding affinity of the Hsp27 proteins to the denatured model
substrate MDH by surface plasmon resonance.
The equilibrium constants obtained for the phosphorylated Hsp27/denatured MDH
combinations demonstrating high binding affinities to the MDH model substrate. However, the
binding affinity constants for the T151I and S135F dimers to MDH are less than the WT with
almost a 5-6-fold difference compared to the WT KD. This may be physiologically relevant as
any change in binding affinities to a substrate in vivo could be catastrophic. In addition, the selfinteractions of the S135F were very strong and although this did not manifest in a decreased
affinity for the denatured model substrate it could potentially affect its association with other
substrates.
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Figure 32. Summary of the substrate transfer assays, shown here with controls, performed with
the Hsp27 proteins WT, T151I, and S135F in their phosphorylated forms. Multiple paired T-test:
dMDH/P. WT 1:1 vs. dMDH/P. T151I 1:1: P = 0.534, dMDH/P. WT 1:2 vs. dMDH/P. T151I
1:2: P = 0.472, dMDH/P. WT 1:3 vs. dMDH/P. T151I 1:3: P = 0.293, dMDH/P. WT 1:4 vs.
dMDH/P. T151I 1:4: P = 0.331, dMDH/P. WT 1:5 vs. dMDH/P. T151I 1:5: P = 0.518, dMDH/P.
WT 1:6 vs. dMDH/P. T151I 1:6: P = 0.077, dMDH/P. WT 1:7 vs. dMDH/P. T151I 1:7: P =
0.016, dMDH/P. WT 1:8 vs. dMDH/P. T151I 1:8: P = 0.223, n= 2 for each assay. Multiple
paired T-test: dMDH/P. WT 1:1 vs. dMDH/P. S135F 1:1: P = 0.648, dMDH/P. WT 1:2 vs.
dMDH/P. S135F 1:2: P = 0.472, dMDH/P. WT 1:3 vs. dMDH/P. S135F 1:3: P = 0.293,
dMDH/P. WT 1:4 vs. dMDH/P. S135F 1:4: P = 0.331, dMDH/P. WT 1:5 vs. dMDH/P. S135F
1:5: P = 0.518, dMDH/P. WT 1:6 vs. dMDH/P. S135F 1:6: P = 0.537, dMDH/P. WT 1:7 vs.
dMDH/P. S135F 1:7: P = 0.363, dMDH/P. WT 1:8 vs. dMDH/P. S135F 1:8: P = 0.957, n= 2 for
each assay.
Table 7. The equilibrium constants obtained from the data analysis of the SPR response curves
generated for the Hsp27/MDH systems and the Hsp27 self-interactions
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4.6 FUTURE WORK
The results of the assays give insight into the chaperoning capabilities of Hsp27 WT in its
complexed and dissociated states and those of the oligomeric and dimeric mutants. However,
there are still some phenomena that cannot be easily explained. Experiments performed by [23,
56] highlight two regions on the Hsp27 molecule that possess protein client binding abilities. The
N-terminal region, as mentioned earlier, is an ideal substrate capturing region due to its slightly
disordered and hydrophobic characteristic and may be better equipped to bind amorphously
aggregating substrates [20, 23, 56]. As for amyloidogenic aggregating substrates the ACD may
be better suited to protect being that it structurally mimics amyloid fibrils of these types of
substrates [23, 56, 58]. Therefore, it will be worthwhile to use a substrate that aggregates via the
amyloidogenic pathway such as α-synuclein [2, 23] to test the chaperoning abilities of the three
proteins whose mutations occur in their β-sheet rich region (the ACD).
Second the assays will be repeated at different temperatures to test the idea of
temperature unlocking higher chaperoning capabilities, specifically the α-lactalbumin assay will
be repeated at a higher temperature. In addition to this assay a second assay using chemical
perturbation to induce aggregation will be employed to rule out the possibility of reducing agent
affecting chaperone ability. Lastly, substrates covering a larger range of molecular weights will
be used to test the molecular weight cut-off theory of Hsp27. In addition, aggregation assays and
SPR assays with the physiologically proven substrates of Hsp27 will be employed. The
physiological substrates α-synuclein and Tau are currently being prepared by our lab. More so

the first ever interaction between the Hsp60/Hsp10 chaperonin complex and the small heat shock
protein 27 has been demonstrated. This setup was used as tool to investigate the substrate-
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transferring or release abilities of Hsp27 however, it opens the door for investigation into a
possible physiologically relationship between Hsp60 and Hsp27.
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Chapter 5 Biophysical Characterization
Dynamic light scattering was used to measure the hydrodynamic radius of the proteins
specifically in comparison to their dimeric counterparts to study the effect of temperature on
their oligomerization capacities. Circular dichroism was used to observe possible secondary
structural changes caused by the mutations that occur within the β-sheet rich ACD. Circular
dichroism was also used to discover if the ACD was a region of binding for the model substrates
utilized (CS and MDH).
5.1 BACKGROUND
Dynamic light scattering is a biophysical method used to measure the hydrodynamic
radius of proteins in solution. Particles in solution demonstrate random thermal motion known as
Brownian motion [108]. This is due to the solvent molecules bumping into and colliding with the
particles or macromolecules suspended in the solvent [108]. This random motion of particles is
influenced by their size meaning that a smaller protein or macromolecule that is struck by a
solvent molecule will be greatly displaced compared to a larger protein [109]. Thus, larger
proteins have slower Brownian motion compared to smaller proteins. This inverse relationship
can be used to extrapolate information such as the size of the protein. The Stokes-Einstein
equation is used to calculate the hydrodynamic radius of a protein which is the diameter of a
protein surrounded by water molecules [109].
A typical DLS instrument is equipped with a laser that shines an incident beam at the
sample [108]. The fluctuations in the scattering of light by the suspended particles is detected by
a photon counting device. This is plotted as the number of photons detected in a very rapid
timescale usually within nanoseconds [110]. The light fluctuations are then processed in a
correlator that is used to compare the fluctuations at regularly interval time periods [110]. The
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correlator compares the fluctuations in intensity and essentially correlates them with each other
[110]. The rate of changes in fluctuations of light scattering is based on the rate of diffusion of
the protein in solution. The diffusion of large proteins is slow, so the intensity fluctuates much
slower. The diffusion of smaller proteins is faster and so the fluctuations in intensity are also
much faster. In this way the instrument can deduce what the size of the protein in solution is
based on its diffusion and scattering of light.
Circular dichroism spectroscopy is also biophysical method that measures the difference
in absorption of right and left circularly polarized light by protein samples [111]. A circular
dichroism instrument is composed of a light source shines light through a filter wheel that
produces monochromatic light at a single wavelength [110, 111]. The light that comes out of the
filter is nonpolarized light that then enters a polarizer that linearly polarizes the light [110].
Before hitting the sample, the light is circularly polarized by passing through a phase plate.
Depending on the properties of the protein sample the remaining light that is not absorbed will
reach the detector [112]. The resulting spectra contains information about the secondary structure
of the protein. Motifs such as β-sheets and α-helices have characteristic absorption patterns of
circularly polarized light [112]. There are numerous programs that can estimate the protein
secondary structure based on references.
5.2 TEMPERATURE MANIPULATION MONITORED BY DYNAMIC LIGHT SCATTERING
Dynamic light scattering experiments were performed using a Malvern Zetasizer.
Following purification Hsp27 WT and mutant proteins were diluted in buffer containing 10mM
Hepes (pH 7.5), 5mM EDTA,1mM TCEP, and 1mM AEBSF to a concentration of 0.5mg/mL.
The sample was placed in a 70µL disposable cuvette and equilibrated at 4°C for 30 seconds.
Measurements were taken in triplicates at an automated count rate distinguished by the built-in
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software. Following readings, the same sample was equilibrated at 37°C for 30 seconds and the
same measurements were taken. This process was repeated at temperatures of 42°C, 50°C, 60°C,
and 70°C then again at 4°C.
For temperature trend analysis the proteins were diluted to a final concentration of 0.5
mg/mL in 10mM Hepes pH 7.5, 5M EDTA, 1mM TCEP, and 1mM AEBSF and subjected to
increasing temperatures. The temperature trend was set to record the hydrodynamic radius and
polydispersity index at a temperature range from 35°C to 55°C in 1°C increments. At each
temperature, the sample was equilibrated for 30 seconds, and triplicates were recorded. The
procedures were repeated for the WT and mutant proteins in their oligomer and dimer
conformations.
5.3 CIRCULAR DICHROISM ANALYSIS
Circular dichroism spectra were recorded on a JASCO-1500 circular dichroism
spectrophotometer in the near-UV region wavelengths 250 nm to 190 nm. Measurements were
taken at intervals of 4, 37, 42, 50, 60, 70, and 80°C then back to 4°C in a 1mm quartz cuvette
with 120-second temperature equilibrations. Hsp27 was diluted to a final concentration of
0.25mg/mL in 10mM sodium phosphate buffered at pH 7.5. For substrate interaction studies
Hsp27 was used at the same previously mentioned concentration at a 5 to 1 molar ratio to MDH
and CS and incubated for exactly one hour at 42°C. All recorded spectra were buffer corrected
and accumulated 5 times at a 0.1nm resolution.
The spectra were averaged and smoothed by a polynomial-fitting program and the inbuilt software was used to convert the raw spectra into molar ellipticity units. After correcting
for protein concentration and amino acid length the data were analyzed using CDPro which
supports the software CONTINLL, CDSSTR, and SELCON3 to report the protein secondary
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structural fractions. Using a 22-protein reference set the secondary structural classes given
included: regular α-helix, distorted α-helix, regular β-strand, distorted β-strand, turns (T), and
unordered (Unrd). The fraction percentages obtained from the three software were averaged and
are reported in the table found in the insets of the CD spectral figures. To monitor possible
secondary structural changes during substrate protection interactions upscaled aggregation assays
using CS and MDH model substrates were examined. The spectra were recorded at time 0 for
each assay at 42°C and again at time 60 minutes.
5.5 RESULTS AND INTERPRETATION
5.6 Hsp27 Oligomerization is Influenced by Changes in Temperature
The Hsp27 oligomeric sample treated at lower temperatures produced populations that
were more polydisperse than samples incubated at higher temperatures. Figure 33A reveals a
correlation between temperature and the average hydrodynamic diameter of complexed WT. As
the temperature is increased the average particle size appears to increase from 12.83 nm to 55.69
nm at 70°C. In addition to an increase in the size of the average diameter the polydispersity of
the sample becomes more homogenous as indicated by a PDI value of .115 for the sample
equilibrated at 50°C. The PDI is known as the polydispersity index and is a measure of the size
distribution of the particles. For reference, values at or below 0.1 are considered moderately
monodisperse and values at 0.05 or lower are extremely monodisperse.
There could be an association between chaperoning ability and the temperature induced
change in the average particle size. To assess whether the increase in size was a consequence of
protein aggregation at elevated temperatures, following the 70°C incubation, the sample was
equilibrated at 4°C for 60 seconds, as shown in Figure 33. The average particle size of the
protein did decrease in size however, not to the size initially observed at 4°C. This could indicate
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that elevated temperatures beyond 60°C represent the heat threshold for oligomeric WT.
Following phosphorylation of the WT oligomer by MAPKAPK2 the WT dimer was subjected to
the same temperature manipulations. Like the WT oligomer there is a steady increase in diameter
when incubated at increasing temperatures from 4°C (6.38 nm) to 70°C (27.64nm).
At lower temperatures, the size of the dimeric protein is confirmed by a diameter that is
about half the size of the oligomer and interestingly approaches the same size as the oligomer at
temperatures 50 and 60°C (Figures 28A and C). At the highest temperature tested the dimer only
reaches an average particle size of 27.86 nm unlike the oligomer’s 55.69 nm diameter. When the
temperature was reverted for the dimeric sample around 70% of the dimer particles were able to
reassemble back into a species that was very close to the original size at 4°C (7.06 nm). The
other 30% of the population remained as higher molecular weight species represented by 23.00
nm. This indicated that the heat threshold for the protein induced in the dimeric conformation is
much higher than that of the oligomer.
To expand on the observed decrease in the polydispersity index as the temperature was
increased a temperature trend study with a narrow range and smaller increments was utilized to
investigate which specific temperatures induced a more homogenous population. Figure 33B
shows the temperature trend for WT oligomer, as the temperature is increased by 1° increments
the average particle size steadily increases. However, there is not a clear trend for the change in
the polydispersity index. Temperatures at 41°C and 45°C represent the lowest PDI values at 0.05
and 0.06, indicative of an extremely homogenous sample distribution. The phosphorylated
conformation of the WT displays a more apparent trend for the size and PDI as the temperature
is gradually increased. The size more than doubles over the tested temperature range and there is
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a more evident decreasing trend for the PDI values. Although the PDI values do not reach as low
as .05 as observed for the oligomer the strong decreasing trend is a notable feature.

Figure 33. Hsp27 WT dynamic light scattering results. (A) Dynamic light scattering
measurements of WT oligomer [0.5mg/mL] subjected to increasing temperatures of 4, 37, 42, 50,
60, and 70°C. (B) Temperature trend of Hsp27 WT oligomer [0.5mg/mL], range 35°C to 50°C at
1° increments. (C) Dynamic light scattering measurements of WT dimer [0.5mg/mL] subjected
to increasing temperatures of 4, 37, 42, 50, 60, and 70°C. (D) Temperature trend of Hsp27 WT
dimer [0.5mg/mL], range 35°C to 50°C at 1° increments.
Due to favorable PDI values at temperatures close to heat shock temperatures for the WT
oligomer, grids were made at the respective temperatures to force a more homogenous
population to obtain an EM reconstruction. The WT oligomer sample at 0.01mg/mL was
preincubated at 41°C according to the temperature generating the most uniform PDI reading.
Supplies such as pipette tips, staining solutions and even the grid itself were preincubated at the
desired temperature. However, despite these efforts to decrease heterogeneity of the WT
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oligomer TEM micrographs (Figure 34) highlight the populations of oligomers remained at
different sizes. The same procedure was applied to the WT dimer. Although the PDI values
representing dimer populations at higher temperatures were not indicative of a monodispersed
distribution, the strong correlation between increased size and decreased PDI values was
favorable. The same method for grid preparation was employed for the WT dimer and Figure
34B shows the types of particles created when a dimer of Hsp27 WT is incubated at elevated
temperatures.

Figure 34. Negative stained micrographs Hsp27 WT. (A), (B), and (C) Hsp27 WT oligomer
prepared at 41°C. (D) Negative stained micrograph of phosphorylated WT (dimer). (E) and (F)
Negative stained micrographs of phosphorylated WT prepared at 42°C.
The mutant proteins were each tested under the same DLS conditions in their
nonphosphorylated and phosphorylated forms. Figures 30 A and C show the average diameter of
mutant protein T151I in its oligomeric and dimeric states, respectively. Like the WT oligomer,
nonphosphorylated T151I displays the same trend upon incubation at higher temperatures with
94

an increase in the hydrodynamic diameter. It also appears to form large irreversible aggregates
upon incubation at 70°C. These aggregates randomly grow larger and become more polydisperse
at 70°C and remain as high molecular weight species (70.69 nm) after the temperature was
reverted to 4°C (Figure 35A).
The trend observed for the T151I dimer is most like that of the WT dimer, with values
very close to those of the WT dimer at each temperature tested and just like the WT dimer a little
over 70% of the T151I was able to reassemble into a species the size initially recorded at 4°C
(Figure 35C). Temperature trend experiments were performed for T151I oligomer and dimer in
the same temperature range. As the WT oligomer did, the T151I oligomer also shows a
correlation of increased temperature with increased size. As the size increases the PDI values do
not exhibit a downward trend, but this could be due to the T151I producing even more
homogeneity representing PDI values, especially at the heat shock temperature of 42°C (0.054).
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Figure 35. Hsp27 T151I dynamic light scattering results. (A) Dynamic light scattering
measurements of T151I oligomer [0.5mg/mL] subjected to increasing temperatures of 4, 37, 42,
50, 60, and 70°C. (B) Temperature trend of T151I oligomer [0.5mg/mL], range 35°C to 50°C at
1° increments. (C) Dynamic light scattering measurements of T151I dimer [0.5mg/mL] subjected
to increasing temperatures of 4, 37, 42, 50, 60, and 70°C. (D) Temperature trend of T151I dimer
[0.5mg/mL], range 35°C to 50°C at 1° increments.
The S135F oligomer generates values in stark contrast to the WT oligomer and instead
more closely resembles a pattern like that of the WT dimer (Figure 33C). Upon incubation to
70°C the complexed mutant protein only reaches 29.74 nm very similar to the WT dimer at
27.64 nm as opposed to the WT oligomer at 55.69nm. This mutant appears to possess the ability
to resist high temperature induced aggregation and reverts to diameter generated between
temperatures 42 and 50°C (Figure 36A) In addition, the reported PDI values for the S135F
oligomer represent a monodisperse population throughout the entire experiment with a reading as
low as 0.032 at 60°C.
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A very interesting outcome occurs when the S135F dimer is tested in the DLS
experiment; the protein does not increase in size as does the WT and T151I dimers do even at
very high temperatures. The largest diameter the S135F dimer reaches is 9.2nm at 60°C and
curiously decreases in size to 7.2nm at 70°C. Therefore, as the temperature increases the
temperature trend data show that only the S135F oligomer increases in size while its dimer
remains at a smaller diameter. In addition, there is a strong correlation for an increased size and
increased homogeneity (represented by PDI values) for the oligomer but as a dimer generates the
highest PDI values of all the proteins.

Figure 36. Hsp27 S135F dynamic light scattering results. (A) Dynamic light scattering
measurements of S135F oligomer [0.5mg/mL] subjected to increasing temperatures of 4, 37, 42,
50, 60, and 70°C. (B) Temperature trend of S135F oligomer [0.5mg/mL], range 35°C to 50°C at
1° increments. (C) Dynamic light scattering measurements of S135F dimer [0.5mg/mL]
subjected to increasing temperatures of 4, 37, 42, 50, 60, and 70°C. (D) Temperature trend of
S135F dimer [0.5mg/mL], range 35°C to 50°C at 1° increments.
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The R136W and R127W monomers were monitored at temperatures 37 and 42°C. At
37°C the monomers 4.66 nm and 5.05 nm. At 42°C the monomers formed large aggregates that
were not resolved upon a decrease in temperature.
5.7 Secondary Structural Changes During Temperature Manipulation and Substrate
Interactions
The Hsp27 ACD is rich in β-sheet structure therefore, circular dichroism was utilized to
study the effects mutations in the ACD had on the secondary structure. The experiments were also
tailored to the DLS experiments to note any secondary structural changes occurring during the
temperature manipulation studies. Hsp27 WT oligomer was incubated at the same temperatures
used for the DLS experiments (with the addition of 80°C). Figure 37 shows the spectra of WT
oligomer thermostated at each temperature. Incubation at temperatures 4°C through 50°C display
no apparent change in the spectra with structural fractions staying relatively the same at 4.1%
(alpha-distorted), 12.46% (beta-distorted), 22.83% (beta-regular), and 24.43% (turn).
As the temperature is increased a change in the signature of the spectra is observed
between temperatures 60°C and 80°C with an increase in the alpha helical percentage and a
decrease in the beta content. Overall, a slight decrease in the unordered fraction from 38% to
34% is observed implying that as the temperature is increased the protein may gain more
secondary structure (Figures 37 A and B). Interestingly when the sample temperature was taken
from 80°C to 4°C the secondary structural motifs reverted close to their original values unlike
during the DLS experiments the sample was not able to regain its initial size at lower
temperatures. This could indicate that temperature has a greater influence on the tertiary structure
than the secondary structure. Although the spectra of the WT dimer at respective temperatures
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are clearly different from the WT oligomer the secondary structural fractions are evidently the
same this is explained by both proteins being made of the same dimeric building block (Figure
37D).

Figure 37. Circular dichroism analysis of Hsp27 WT. (A) CD spectra of WT oligomer
thermostated at temperatures 4, 25, 37, 42, 50, 60, 70, 80, and 4°C* (B) The secondary structural
fractions estimated from the CDPro software package that uses programs Continll, CDSSTR, and
SELCON3 to average the estimated secondary structural fractions. The three software estimate
the secondary structural fractions by using a 22-protein reference set and specialized algorithms
to deconvolute the secondary structure information contained within the spectra. (C) CD spectra
of WT dimer thermostated at temperatures 4, 25, 37, 42, 50, 60, 70, 80, and 4°C*. (D) The
secondary structural fractions estimated from the CDPro software package that uses programs
Continll, CDSSTR, and SELCON3 to average the estimated secondary structural fractions. The
three software estimate the secondary structural fractions by using a 22-protein reference set and
specialized algorithms to deconvolute the secondary structure information contained within the
spectra.
To elucidate possible secondary structural variations caused by the ACD mutations
circular dichroism measurements were taken at the physiologically relevant temperatures of
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37°C and 42°C. At these temperatures, the spectra for WT oligomer, dimer and T151I oligomer
were practically superimposable as were the spectra for the S135F and R136W mutants in their
oligomer and dimer forms. According to the secondary structural fractions generated by using
the combined software Continll, CDSSTR, and SELCON3 all proteins revealed to contain
majority β-sheet structure, attributed to the core alpha-crystallin domain Figure 38. The structural
percentages of the regular β-sheet, S(r), represent the second largest secondary structural fraction
of all the proteins. The Turn fractions encompass a large fraction of the secondary structure as
well most likely representation of the beta-turn between the β-strands in the ACD.
The proteins with ACD mutations appear to have more β-structure content and are
generally less disordered than the WT oligomer, dimer and T151I dimer. As mentioned, the S(r)
fraction representing a regular antiparallel β-sheet was the highest for the S135F and R136W
mutations in either conformation, this could be attributed to a stabilizing mutation occurring at
the dimer interface. The mutations at positions 135 and 136 are both converted from a polar
amino acid to large hydrophobic/aromatic amino acids (phenylalanine and tryptophan). These
mutations could have an effect in stabilizing the internal dimer interface through enforced
hydrophobic interactions and could be a possible explanation for the increase in secondary
structure of these mutants.
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Figure 38. Circular dichroism of Hsp27 proteins at elevated temperatures. (A) CD spectra of all
proteins thermostated at 37°C (B) The secondary structural fractions estimated from the CDPro
software package that uses programs Continll, CDSSTR, and SELCON3 to average the
estimated secondary structural fractions. The three software estimate the secondary structural
fractions by using a 22-protein reference set and specialized algorithms to deconvolute the
secondary structure information contained within the spectra. (C) CD spectra of all proteins
thermostated at 42°C. (D) The secondary structural fractions estimated from the CDPro software
package that uses programs Continll, CDSSTR, and SELCON3 to average the estimated
secondary structural fractions. The three software estimate the secondary structural fractions by
using a 22-protein reference set and specialized algorithms to deconvolute the secondary
structure information contained within the spectra.
Figure 39 show the CD spectra of the CS assay performed with WT oligomer (A) and
WT dimer (B). It appears for the WT oligomer there is a gain in secondary structure denoted by
structural fractions S(r) and S(d) from 13.73% to 25.27% and 8.93% to 13.23%, this correlates
with protection abilities of WT oligomer toward CS. Figure 39B also displays an increase in βsheet content for the WT dimer with values increasing from 15.4% to 19.1% S(r) and 8.0% to
10.6% S(d), and the WT dimer has a propensity to protect according to the assay. Interestingly
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when the reaction was repeated for WT oligomer and dimer in the presence of denaturing MDH
the S(r) and S(d) actually experience an overall decrease in β-structure from 14.55% to 11.9%
for the S(d) and actually a minimal gain of the S(r) fraction from 19.5% to 21.15%, these
decreased (distorted β-sheet) and minimally increasing (regular β-sheet) values associate with no
protective capabilities of WT oligomer for MDH. The S(r) and S(d) fractions for the WT dimer
display a large decrease in secondary structure yet in the assay have chaperone abilities, it should
be noted however that the spectra in Figure 39D at 60 minutes appears to be unchanged in
comparison to the spectra at time 0.

102

Figure 39. Substrate interaction studies of Hsp27 WT to model substrates CS and MDH
measured by circular dichroism. (A) Upscaled CS/WT oligomer assay at times 0 and 60 minutes
monitored by CD, inset displays secondary structural fractions computed by the CDPro software
package. (B) Upscaled CS/WT dimer assay at times 0 and 60 minutes monitored by CD, inset
displays secondary structural fractions computed by the CDPro software package. (C) Upscaled
MDH/WT oligomer assay at times 0 and 60 minutes monitored by CD, inset displays secondary
structural fractions computed by CDPro software package. (D) Upscaled MDH/WT dimer assay
at times 0 and 60 minutes monitored by CD, inset displays secondary structural fractions
computed by the CDPro software package.
The citrate synthase aggregation assay performed in the presence of T151I oligomer
produced similar results as that of the WT oligomer with gains in secondary structures of 16.7%
to 20.2% (regular β-sheet) and 8.43% to 12.13% (distorted β-sheet). This correlated with high
chaperoning activity of T151I oligomer. As for the dimer of T151I the S(r) fractions experienced
a minimal loss in secondary structure from time 0 (23.53%) to 60 (22.27%) and was practically
unchanged for the S(d) fraction, 11.93% to 11.8% (Figure 40B) and associated with protective
abilities for CS. The oligomer of T151I experiences a minimal decrease in β-sheet structure
represented by the S(r) fraction 23.4% to 22.23% and shows an almost negligible increase in the
distorted β-structure from 12.37% to 12.53% and as mentioned earlier exacerbates the
aggregation effect of MDH. Finally, the T151I dimer displays a pattern that a gain in secondary
structure correlates with chaperone activities; the S(r) and S(d) fractions each increase from
24.17% to 26.10% and 13.17% to 14.2%, respectively (Figure 40D).
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Figure 40. Substrate interaction studies of Hsp27 T151I to model substrates CS and MDH
measured by circular dichroism. (A) Upscaled CS/T151I oligomer assay at times 0 and 60
minutes monitored by CD, inset displays secondary structural fractions computed by the CDPro
software package. (B) Upscaled CS/T151I dimer assay at times 0 and 60 minutes monitored by
CD, inset displays secondary structural fractions computed by the CDPro software package. (C)
Upscaled MDH/T151I oligomer assay at times 0 and 60 minutes monitored by CD, inset displays
secondary structural fractions computed by the CDPro software package. (D) Upscaled
CS/T151I dimer assay at times 0 and 60 minutes monitored by CD, inset displays secondary
structural fractions computed by CDPro software package.
The experiment performed with CS and S135F oligomer also produced values of
increased secondary structure (Figure 41A) S(r) – 12.73% to 16.47% and S(d) – 7.7% to 9.3%
that associate with protective activity. The dimer of S135F incubated with CS resulted in the
same increase of secondary structure and retains activity. (Figure 41B) shows increased values of
15.83% to 17.17% and 8.33% to 10.4% for regular and distorted β-sheets, respectively. The
spectra for the S135F oligomer incubated with MDH show spectra that are relatively unchanged
and almost superimposable. There were, however, decreases in secondary structure but they were
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essentially negligible; (23.6% to 22.67%) for regular and (12.37% to 12.27%) for distorted βstructures. Interestingly the S135F oligomer can protect MDH but this protective effect is only
slightly above 50%. Lastly the S135F dimer displayed decreases in secondary structural fractions
(Figure 41D) but has the most protective tendencies towards aggregating MDH.

Figure 41. Substrate interaction studies of Hsp27 S135F to model substrates CS and MDH
measured by circular dichroism. (A) Upscaled CS/S135F oligomer assay at times 0 and 60
minutes monitored by CD, inset displays secondary structural fractions computed by CDPro
software package. (B) Upscaled CS/S135F dimer assay at times 0 and 60 minutes monitored by
CD, inset displays secondary structural fractions computed by CDPro software package. (C)
Upscaled MDH/S135F oligomer assay at times 0 and 60 minutes monitored by CD, inset
displays secondary structural fractions computed by CDPro software package. (D) Upscaled
CS/S135F dimer assay at times 0 and 60 minutes monitored by CD, inset displays secondary
structural fractions computed by the CDPro software package.
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5.6 DISCUSSION
The aggregation assays suggests that the dimer is responsible for recognizing and
stabilizing thermally denaturing model substrates with oligomerization and subunit dynamics
essential to its function. It was also revealed that there is a possible gain in secondary structure
upon binding a specific substrate. The location of the mutated residues occurring in the ACD of
the dimeric interface of proteins S135F, R127W, and R136W produces an overall increase in
protection capacities and an increase in size based on the DLS results as well as secondary
structure based on the CD spectra.
The T151I mutant behaves like the WT indicating that for oligomerization, chaperoning
ability, and secondary structure this mutation does not affect any major motifs. After all the
S135F, R136W, and R127W mutations occur right at the dimer interface groove essentially these
substitutions have altered the composition while the T151I mutant only occurs near the β4/β8
groove. Obtaining a single-particle reconstruction of the “storage state” complex of Hsp27 WT
will reveal how chaperone active dimers organize into higher molecular weight orders and 3D
structures of the mutant proteins will reveal what effects the mutations have on the quaternary
structure of Hsp27 therefore, efforts to homogenize the distribution of oligomers will continue.
Dynamic light scattering experiments performed at a range between 35°C – 50°C with 1°
increments revealed the influence of temperature on oligomerization patterns. As the temperature
is steadily increased WT oligomer, WT dimer, T151I oligomer, and S135F oligomer demonstrate
an increase in the overall average hydrodynamic diameter. The oligomer of S135F experienced
the largest increase from 15.68nm to 21.22 nm and T151I oligomer experienced the smallest
increase from 13.62nm to 15.35nm. Interestingly, in contrast to the WT dimer, the dimers of
T151I and S135F did not display a significant increase in size. These differences highlight the
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rigidity of the mutant dimers, thus exemplifying the importance of the dynamic nature of the
Hsp27 protein.
At the physiological temperatures of 37°C and 42°C the oligomer of any protein was
always larger than its dimeric counterpart. Another notable feature is that the mutant oligomer
S135F is substantially larger than the WT oligomer, even the protein incubated at 37°C is larger
than WT oligomer at 42°C. The T151I oligomer had oligomerization patterns most resembling
the WT oligomer. These findings suggest that mutations in the dimer interface affect
oligomerization dynamics more so than mutations near the hydrophobic groove. The mutant
S135F produces the most interesting size distributions as an oligomer and a dimer, taking the
place as the largest inducible species and the smallest. In addition, the S135F oligomer has the
most monodispersed distribution at a wider range of temperatures further supporting the notion
that disruption of polydispersity has a negative consequence in terms of disease progression
In summary the hydrodynamic diameters of the proteins studied in their complexed and
dissociated states were graphed for comparison purposes at the two important physiological
temperatures 37 and 42°C (Figure 42). It can be confirmed that in each run the oligomer of any
protein was always larger than its dimeric counterpart for the two temperatures selected. It can
also be seen that there is a large increase in size for the dimers of WT and T151I as the
temperature is increased but for the remaining oligomer proteins and the S135F dimer the
increase in size is minimal. The R136W and R127W purified as monomers are unstable at
elevated temperatures (Figure 42). These proteins are highly unstable and irreversibly aggregate
which explains why they aggravated precipitation during the aggregation assays. The T151I
protein in oligomer and dimeric states once again most closely resembles the WT.

107

These findings suggest that mutations at the dimer interface affect oligomerization
dynamics. This could be due to the substitution to a hydrophobic residue which could potentially
stabilize the transient interactions made with the NTR. These data in relation with aggregation
assay results support the dimer as the better chaperoning entity. Increased temperature induces
faster subunit exchange rates so although the dimers organize into larger complexes at elevated
temperatures it could signify faster subunit exchange which allows for more opportunities to
capture substrate. During the DLS experiments there are no substrates to bind so instead the
dimers may organize into a larger storage state whereas they would be available at a faster rate to
bind and protect substrates.
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Figure 42. Summary of the DLS results comparing the hydrodynamic radii of the Hsp27 proteins
in their nonphosphorylated and phosphorylated states. Multiple paired T-test: WT Oligomer vs.
T151I Oligomer P = 0.753, WT Oligomer vs. S135F Oligomer P = 0.010, WT Oligomer vs.
Phosphorylated WT P = 0.008, Phosphorylated WT vs. Phosphorylated T151I P = 0.214,
Phosphorylated WT vs. Phosphorylated S135F P = 0.431, WT Oligomer vs. R136W P = 0.0004,
WT Oligomer vs. R127W P = 0.0005, n= 3 for each protein at 37°C. T-test: WT Oligomer vs.
T151I Oligomer P = 0.038, WT Oligomer vs. S135F Oligomer P = 0.0005, WT Oligomer vs.
Phosphorylated WT P = 0.034, Phosphorylated WT vs. Phosphorylated T151I P = 0.051,
Phosphorylated WT vs. Phosphorylated S135F P = 0.003, WT Oligomer vs. R136W P = 0.0001,
WT Oligomer vs. R127W P = 0.00002, n= 3 for each protein at 42°C.
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Chapter 6: Creating a Model for Charcot-Marie-Tooth Disease: Drosophila Melanogaster
6.1 BACKGROUND
Drosophila melanogaster is a powerful model organism that has been used to study many
human diseases [113, 114]. The fruit fly has a small and simple genome encompassing only four
chromosomes, yet it shares many equivalent genes with the human genome [113, 114]. Many
genes that cause disease in humans can be found in the Drosophila Melanogaster genome [113,
114]. Other benefits of using Drosophila Melanogaster include the ease of production and
inexpensive maintenance [113]. They have a short life cycle and produce many offspring
enabling quick detection of changes [114]. It is relatively easy to genetically modify fruit fly
genes and create transgenic models that can express most proteins of interest.
Generating a transgenic fly line first involves molecular cloning. The gene of interest is
cloned into an expression vector that is inducible in fruit flies [115]. The construct is injected
into fly embryos that eventually develop into larvae [113]. The larvae mature into flies and the
flies that contain the transgene in the germ cells are selected and backcrossed over many
generations to minimize multiple random insertions of the construct. Once the fly lines have
been stabilized by balancer flies it is necessary to map the insertion of the transgene [114]. This
required only if the vector was randomly incorporated into the genome. This involves a process
of making specific genetic crosses with balancer flies to map the chromosome of the transgene.
The benefits of this are varying expression levels of your transgene across different fly lines.
The Gal4/UAS system allows for control of the expression of a gene of interest within the
fruit fly model organism [115]. There are several Gal4 lines which are genetic variants of
Drosophila Melanogaster models that contain different promoters that express the Gal4 protein
in any subset of neuronal cells [115, 116]. The Gal4 protein is a transcriptional activator derived

110

from yeast that binds an enhancer sequence known as UAS that is upstream a promoter [115117]. The Gal4 protein binds the promotor and recruits fly cellular machinery to induce
expression at this promotor site. The transgene is placed downstream of the UAS, and so
selective expression of the transgene can be controlled depending on the which cells express the
Gal4 protein [115, 116]. To control differential expression, fly lines that contain the transgene
placed downstream the UAS sequence can be crossed with any fly line that contains a Gal4
promoter. The resulting progeny will contain the transgene in every type of cell within the model
organism, but expression will only occur in the cells that express Gal4.
Drosophila Melanogaster model systems for CMT and dHMN with mutations in the
HspB1 gene are lacking [118-120]. There was one study that produced an S135F mutant
transgenic fly line as a model for dHMN [121]. Aside from this there are no verified fruit fly
models linked to mutations in the HspB1 gene. Our collaborative work with Dr. Han included
creating a Drosophila Melanogaster model for CMT2F associated with the HspB1 mutations:
R127W, S135F, R136W, T151I, and P182L. Behavioral assays such as adult climbing ability,
flying patterns, and larval locomotion will be conducted to determine whether the peripheral
nervous system is exclusively affected by CMT2F or if the central nervous system is also
affected. Larval locomotion behavioral assays are especially useful in examining the effects of
human disease genes on their movement. Immunostaining experiments will also be conducted to
track the localization of the Hsp27 proteins throughout the fly system.
6.2 CLONING THE HSP27 CONSTRUCTS BY THE GATEWAY SYSTEM AND PREPARING THE HSP27
TRANSGENIC FLY LINES
The six entry vectors containing the HspB1 genes WT, R127W, S135F, R136W, T151I
and P182L were cloned via the gateway system into p-element destination vectors. The 6 genes
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were each cloned under UAS in pTW and pTWG vectors. The latter contains a GFP tag that is
fused to the c-terminal end of the expressed protein. The p-element destination vectors contain a
white+ selectable marker for selection of flies containing the transgene [122]. Only the pTW
vectors containing WT and the 5 mutants and the WT pTWG constructs were outsourced to
Rainbow Transgenic Flies for insertion into larval embryos. This was done to minimize the
workload of handling various fly lines.
The transgenic flies were backcrossed with white flies for six generations. For each
Hsp27 construct male and female flies that contained the mini-white gene* (phenotypically
displaying as colored eyes) were selected and crossed with white flies (white eyes). Backcrossing
ensures fly chromosomes only contain one copy of the Hsp27 transgene. In each cross setup 3 to
5 transgenic females were collected soon after eclosion. This ensured that the females were
virgins as to not introduce any genetic variables. The transgenic males were also collected and
mated with white virgin flies. This was continued until 10-20 fly lines were created for each
Hsp27 construct. The fly lines were separated and organized based on the intensity and color of
their eyes. Darker eye color is indicative of multiple insertions of the transgene while lighter eye
color typically corresponds to one insertion of the transgene into the chromosome. All the
different fly lines were maintained in vials that contained a standard recipe for cornmeal agar.
The vial stocks were periodically watered to retain humidity and flies were rotated into new vials
every 3 to 4 weeks. To ensure healthy fly lines culling and selecting out undesirable flies (such
as white flies or sickly-looking flies) was performed regularly. For ease of control, the flies were
anesthetized on a fly pad that diffuses carbon dioxide and observed under a stereoscope.
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6.2.1 Mapping Chromosomal Location of Hsp27 Transgenes
Ten to twenty fly lines were obtained for each of the seven constructs. They were then
mapped by setting up genetic crosses with the balancer flies CyO and TM3, Sb that carry the
genetic markers for curly wings and stubbly hair, respectively. To start the mapping, colored eye
virgins were collected from each fly line soon after eclosion. They were placed in new vials for 3
days to ensure they were truly virgins, if there were eggs or larvae present the entire vial of flies
was discarded. The colored eye virgins were crossed with curly stubble males, these are male
flies that are double balanced and carry the genetic markers for curly wings and stubbly abdomen
hair. The flies were allowed to mate and 7 to 10 days later the progeny was collected and
examined. This was the first cross in a two-cross step up.
An example of a genetic cross can be seen in Table 8: if the transgene is located on the X
chromosome the genotype of the female fly is Tg(mw)/w; +/+; +/+. The Tg(mw) stands for
transgene and the (mw) represents the phenotypical colored eyes, therefore the flies containing
the transgene can be easily recognized. The plus signs represent the WT version of that gene.
The genotype representing the first three chromosomes are only denoted as the fourth
chromosome is so small it usually is not the location for a transgene. The genotype of the male
balancer flies used is w/Y; +/CyO; +/Sb where the Y stands for male and the CyO and Sb stand
for curly and stubble. The CyO gene balances the second chromosome, and the Sb gene balances
the third chromosome. Therefore, by making selective crosses and examining the resulting
progeny it is possible to deduce which chromosome the transgene is located in.
Table 8: Genetic Outcomes if Transgene is on X Chromosome
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The left table (Table 8) represents the possible outcomes of the first, second, third
chromosomes if a virgin with the transgene located on the X chromosome is mated with a CyO
Sb male. The table on the right list all the relevant genotypes of the resulting progeny plus a
description of their phenotype. Therefore, if the assumption that the transgene is on the X
chromosome was correct then all the progeny will have colored eyes. An easier method was
employed to learn if the transgenes were located on the X chromosomes. This alternate method
did not require the use of curly and stubble males. Virgin white eyed females were collected and
mated with colored eye males of the same fly line. This was a quick way to get a yes or no
answer if the transgene is located on the X chromosome. Validation that the transgene is on the
X chromosome occurs if all the females of the resulting progeny have colored eyes and all the
males have white eyes. That is because males only have one X chromosome, if the transgene is
on the X chromosome, then only the female progeny will have colored eyes since it is not
possible for the X chromosome with the transgene to be passed down to the male progeny. Of the
eighty-six fly lines tested in this way only 15 lines were confirmed to have the transgene on the
X.
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The remaining fly lines were tested by setting up genetic crosses like Table 8. Except in
these cases the transgene was assumed to be on the second or third chromosomes. The resulting
phenotypes of the F1 progeny would be a mixture in both cases. Some males and females would
be combinations of colored eyes, white eyes, curly, stubble, and no marker. Because of this a
second cross was required to finish mapping the genotypes of the fly lines. After the colored eye
virgins were crossed with the curly stubble males all the progeny with colored eyes and balancer
phenotypes were collected and separated based on gender. Ideally colored eye males and females
with both balancer phenotypes were collected because this would require only one cross to
acquire the answer. Table 9 represents the genetic outcomes in the case that the transgene was
located on the second chromosome or the third chromosome and the resulting genotypes and
phenotypes of the progeny.
Table 9. Genetic Outcomes if Transgene is on 2nd or 3rd Chromosomes

The F2 progeny were collected after eclosion and examined. If an ideal cross of a male
and female with both balancer markers from the F1 generation were crossed, the answer of
which chromosome the transgene is on would be known. Table 9 lists the relevant genotypes and
phenotypes that would result from the ideal cross. All progeny from these two types of crosses
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would have colored eyes, the difference would be in the intensity of the colored eyes. For
example, if the transgene were on the second chromosome flies with no markers and with the
stubble marker would have intensely darker colored eyes. If the transgene were on the second
chromosome the opposite case would be true. This is because the progeny having darker colored
eyes is a result of containing two copies of the transgene. Some fly lines did not produce progeny
with both markers, in these cases double crosses were made to ensure the location of the
chromosome. For example, a combination of two crosses for the second chromosome were set
up: w/w; Tg(mw)/CyO; +/+ x w/Y; Tg(mw)/CyO; +/+ or w/w; Tg(mw)/CyO; +/Sb x w/Y;
Tg(mw)/CyO; +/+. If the male and female in the cross only share one marker, then a second
cross has to be set up where they both share the other marker as well. This was done to acquire
comprehensive results and to obtain a definitive answer as the double cross gives. Using these
crossing techniques forty-six fly lines were mapped.
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Chapter 7 Conclusions and Future Directions
7.1 MAJOR CONCLUSIONS
In this study the effect of mutations in the alpha-crystallin domain of Hsp27 that associate
with neurodegenerative disorders Charcot-Marie-Tooth Type 2F and distal Hereditary Motor
Neuropathy II were investigated. The oligomerization and secondary structural perturbations
produced by the disease-causing mutants were examined. Additionally, the conformation of
Hsp27 was analyzed to determine the role of the Hsp27 state in terms of chaperoning ability.
Hsp27 can exist in two conformational states: as a large complexed multimer and as dissociated
subunits. The consequence of these two conformations on chaperone effectiveness was
monitored by using four established aggregation assays.
In accordance with the assays, it is apparent that the dissociated form of Hsp27 WT
contains the most potent chaperoning ability for thermally denatured substrates. The WT
oligomer fails to protect the thermally denatured model substrates yet can protect the chemically
denatured model substrate. Altogether Hsp27 WT, depending on its conformation, can prevent
the aggregation of the four model substrates utilized in this study. These two states serve
dynamic roles within the cell and are possible modes of regulation between the many duties of
Hsp27. These data suggest that when one state of Hsp27 is not able to protect a given substrate
the other conformation of Hsp27 gains the ability to chaperone that specific substrate, possibly
allowing the chaperone molecule to protect a wide range of substrates.
The three proteins with ACD β-sheet mutations (S135F, R136W, and R127W) display
slightly higher chaperone activity than the WT during the thermal aggregation assays in their
dimer states. In addition, they also contain more antiparallel β-sheet secondary structure than the
WT and are substantially much larger than the WT oligomer according to the DLS results. The
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R136W and R127W purified as monomers had abolished chaperone activity suggesting that the
substitution from arginine to tryptophan in the dimer interface is more deleterious. The
complexed and dissociated T151I mutant protein, with its mutation in the connecting loop of the
ACD, displays similar results to the WT in terms of chaperone abilities, secondary structure, and
oligomerization patterns. Mutations in the dimer interface groove affect oligomerization
dynamics and secondary structure more so than mutations in the connecting loop of the ACD.
Aggregation assays using the model substrate CS were monitored by circular dichroism
to assess the secondary structural changes occurring during chaperone/substrate interactions.
Interestingly this model substrate was the only one protected by all the proteins in their oligomer
and dimeric states. When recorded, there appeared to be an overall pattern of high chaperone
capabilities correlating with an increase in total β-sheet content. This data implies that the ACD
may be a region for capture of denatured CS, however it is also observed that the mutations in
the ACD do not negatively affect chaperoning ability and instead may result in an undesirable
gain-of-function. In vitro the differences are not staggering however, these subtle changes may
have a larger effect in vivo with physiological substrates implying that Hsp27 with mutations in
the ACD dimer interface may unnecessarily bind important proteins. This is further supported by
the amino acid replacements to large hydrophobic/aromatic groups that can bind hydrophobic
regions of denatured substrates more effectively. Disease progression may ensue when the
aberrant proteins bind important neural proteins and decrease their availability in crucial cellular
pathways.
The ability of small heat shock protein to transfer, release, or cooperatively coordinate
the release of its substrate is a crucial process in the proteostasis pathway. The Hsp60/Hsp10
chaperonin complex was used as a tool to assess the substrate transferring abilities of the
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phosphorylated mutant proteins. The chaperone activity of phosphorylated T151I and S135F
mutant proteins in protection of the model substrate MDH were comparable if not slight better
than the phosphorylated WT. Deficits in chaperoning activity may reveal themselves during the
transfer of a model substrate for refolding. The substrate transfer assays demonstrated that an
abundance of Hsp27 is necessary to completely protect a substrate from denaturation. As the
ratio of Hsp27 to the substrate was steadily increased the reactivation signal of MDH was also
increased. This could also suggest that the transient self-interactions made by Hsp27 may have a
role in transferring or releasing the model substrate. The mutant dimers did not display decreased
transferring/releasing activity however SPR analyses revealed that the WT dimer affinity to the
model substrate MDH is stronger than for the mutants/substrate systems.
In addition, the SPR kinetic analyses revealed that the self-interactions of the WT dimer
are a lot weaker than the self-interactions of the WT oligomer. This is reasonable as
phosphorylation of the NTR serine residues results in dissociation of the oligomers. Our data
show that strong self-interactions with binding affinities in the nanomolar range correlate with
decreased chaperone activity while weak self-interactions correlate with enhanced chaperone
activity. This supports the idea that the transient self-interactions of the Hsp27 protein may have
a role in regulating chaperone protection and substrate release. Interestingly, the phosphorylated
S135F mutant has high binding affinities to the model substrate and to itself. The amino acid
substitution of a serine to a hydrophobic phenylalanine may serve to increase the interaction time
between the dimer interface groove and regions on the NTR that result in elevated binding
affinities. This could potentially be problematic as the regulation of binding and releasing client
proteins could be disturbed.
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7.2 FUTURE DIRECTIONS
There is still much work to do in the investigation of Hsp27 and its role in human disease.
During my work, I have set the groundwork for many future Hsp27 endeavors. I have cloned and
established protein prep and purification protocols for 18 Hsp27 variants, these include the
disease mutants and the NTR and CTR variants, not including the MAPKAPK2 protein. I have
optimized protocols for assessing chaperone activity in vitro and I have created an additional
assay that monitors the transfer of substrate and notably highlights a never before reported
relationship between the chaperonin Hsp60 and Hsp27. My research has contributed to the field
of the small heat shock protein community by providing insight into how Hsp27 may interact
with its substrate. This has potential clinical implications for efforts in drug development which
could target reduction of the interaction between mutant Hsp27 and its substrates. This could
alleviate symptoms of neuronal damage by stabilizing the availability of vital proteins involved
in neuronal pathways. In addition, my collaborative work in creating a Drosophila Melanogaster
model for CMT2F and dHMNIIB is important. A working model for each of the mutations that
cause CMT2F and dHMNIIB would be invaluable in studying the pathological mechanisms of
these neurodegenerative diseases. In addition, it will provide a platform to study and test
potential drug candidates for the prevention or reversal of these neurodegenerative disorders.
Ongoing efforts in the Hsp27 project include cloning and purifying the physiological
substrates of Hsp27, these include α-synuclein and PNS Tau. Aggregation prevention assays
using these physiological substrates will be performed to assess whether the mutant proteins
have deficits in chaperoning of these proteins. Additionally, the physiological substrates will be
used to stabilize the Hsp27 oligomer to generate a single particle 3D reconstruction. A 3D
reconstruction will be vital in understanding the mechanism of disease progression at the atomic
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level. Additionally, the NTR variant with three serine mutants will be further studied to test
whether mutation at the three key serine residues will halt dimer formation. This will be
important in understanding if the oligomer of Hsp27 also possesses chaperoning activity or
mainly functions as a storage state for chaperone active dimers. Furthermore, the mutant may
stabilize higher order oligomers facilitating another route to obtain a 3D reconstruction.
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